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Abstract 
Breast cancer continues to be the number one cause of new cancer cases and 
second in mortality rate in Canadian women. For over 40 years researchers have shown 
a statistical link between obesity and breast cancer. Obesity has been linked to many 
non-communicable diseases but researchers are now showing several cancers are linked 
to obesity, including breast. Specifically, post-menopausal women are at increased risk 
to developing and dying from breast cancer with increased adipose "fat" tissue. 
Although adipose tissue in the past was considered an inert storage depot, we now 
know it produces and secretes the adipokines adiponectin and leptin. Lean individuals 
have been shown to have higher circulating levels of adiponectin and lower levels of 
circulating leptin, which ultimately alters the ratio between the two adipokines. 
Adiponectin has been shown to bind to its membrane receptor ADIPORl and activate 
the cell signalling pathway AMPK which directly stabilizes the cell cycle inhibitor prntein 
p27. The effects of both adiponectin and leptin on ADIPORl have yet to be shown. 
Therefore the purpose of this thesis was to look at ADIPORl function, stability and 
regulation in order to determine what affects both adiponectin and leptin have on 
ADIPORl. The results show that adiponectin is able to increase ADIPORl protein content 
while increases the amount of pAMPK and decreasing the amount of pAkt. I also show 
that upregulating ADIPORl can overcome the deleterious effects of LEP treatment and a 
HFD/obesity on cell cycle regulating proteins. 
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1. INTRODUCTION 
Cancer continues to be one of the leading causes of mortality in Canada, yet over 
the past 10 years these death rates have been steadily dropping. One explanation is 
better early detection as we begin to understand the mechanisms behind cancer 
development and the many factors which influence cancer progression. Breast cancer 
mortality specifically has been shown to have decreased by :::: 2% since 1998 while the 
incidence rate continues to rise in part due to better detection 1• This decrease in overall 
percent mortality should not be confuse~ with an actual increase in the absolute 
number of deaths, further stressing the importance of breast cancer research. 
Recent statistics from the Canadian Cancer Society predict in 2012 that an 
estimated 22,700 women will be diagnosed with breast cancer and 5,100 will die of it 1• 
That equates to roughly 1 in every 9 women will develop breast cancer and 1 in every 40 
dying from the disease. Breast cancer ranks 1st in incidence for Canadian women and 
only 2"d in mortality, closely behind lung cancer. As so many women become affected by 
this disease it has become important to look at the molecular events which cause breast 
cancer progression as well as epidemiological trends to better help prevent breast 
cancer development. 
Cancer in its simplest form is a disease of the mammalian cell cycle. Under 
normal circumstances, the mammalian cell cycle is a tightly regulated series of events. 
The cell monitors extracellular signals and determines when appropriate to enter the 
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cell cycle to repair or replace damaged cells. Upon receiving a mitogenic signal, the cell 
is prompted to begin dividing in order to produce two identical daughter cells. During 
the cell cycle there are check points where mistakes are noted and either fixed or the 
cell is terminated. A tumor cell on the other hand is no longer under proper function 
and control which can lead to the cell und_ergoing uncontrolled proliferation. 
In order to properly understand how this transition from controlled growth to 
uncontrolled cell growth occurs, it is necessary to understand the events and 
mechanisms which govern a normal mammalian cell cycle as well as how these 
mechanisms are altered in cancer progression. 
1. The Mammalian Cell Cycle 
The mammalian cell cycle is an extremely important process which is tightly 
regulated and involves multiple stages for successful division. Originally the cell cycle 
was divided into to two primary phases known as mitosis (M phase) and interphase, the 
interlude between two M phases 2• Cell division occurs within M phase where a cell 
undergoes a controlled division to produce two identical daughter cells. Although M 
phase is important for cell division, the majority of the time spent by our cells is within 
interphase. lnterphase itself can be further divided into three stages known as gap one 
(Gl), synthesis (S) and gap two (G2) phases. The replication of genetic material or DNA, 
occurs within a specific part of interphase known as S phase. S phase is preceded by Gl 
phase and followed by G2 phase, where a cell must prepare for DNA synthesis or 
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prepare for mitosis, respectively 3• These gap phases allow for the cell to repair any DNA 
damage or replication errors. If the DNA damage cannot be repaired, under normal 
circumstances the cell will induce the process of cell death (apoptosis) 4• It is also 
important to note that cells within Gl can enter a quiescent state known as Go but this 
is done before the cells commit to the replication of DNA 2• The majority of cells in our 
body which are normally non-proliferating remain in this quiescent state of Go until they 
are stimulated by an external mitogenic signal to divide. Arguably one of the most 
important phases is the Gl phase as this is the point in the cell cycle where a cell 
commits to replicate the DNA and undergoes cell division 3• Gl is the period where the 
cell evaluates its surroundings (ie. environment, stress) and determines whether it 
should continue to divide or regress back into G0• Also within Gl phase, many signals 
intervene in order to influence cell division and the deployment of the cells 
developmental programme 3• 
1.1 Regulation of the Cell Cycle 
The transition between one phase to another is governed by different cyclin 
dependent kinases (cdks), which act as regulatory enzymes. These kinases are a family 
of serine/threonine kinases which are activated at specific points throughout the cell 
cycle in order for progression to occur 2• Five cdks have been found to be active during 
certain phases of the cell cycle which include Cdk2/4/6 {Gl), Cdk2 (S phase) and Cdkl 
{G2), all of which when activated induce downstream processes by phosphorylating 
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certain proteins 5• What's important to note is that cdks act in combination with unique 
regulatory cyclin proteins in order to form Cdk-activating complexes (Figure 1). 
Rb Depllosphoryl~1tio11 
p2l~Cyclin 
P27 BIA + p57 Cdkl 
Cyclin A + Cdk2 
IN1{4: 
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+ Cdk2 I --7 p~ 
Figure 1: A simplified diagram of the mammalian cell cycle showing the cyclin/cdk 
complexes and the inhibitor proteins (INK4 and KIP) which affect them. Modified 
from Slingerland and Pagano, J Cell Physiology, 2000 
The cdks require this binding to their cyclin subunit to allow it to become 
catalytically active 6• Different members of the cdks, along with their regulatory cyclins, 
act as key switches throughout the cell cycle to allow for further progression. Cdk 
protein levels remain constant throughout the cell cycle which is in contrast to their 
4 
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regulatory proteins the cyclins. As the name suggest, cyclin proteins are either 
accumulated or degraded during the cell cycle which allows them to periodically 
activate their cdks. The cyclins can be upregulated by cycles of transcription and 
translation to increase their protein levels or they can be degraded by ubiquitin 
mediated proteolysis to decrease protein levels 7• An additional mechanism by which 
the cdks become active is through the phosphorylation of different residues within their 
activating segments which induces a conformational change to enhance its· binding of. 
the cyclins 4• This includes the Weel kinases which phosphorylate cdks with an 
inactivating phosphorylation. The enzyme cdc25 is a phosphatase which 
dephosphorylates the same sites that are phosphorylated by Weel removing inhibition 
and allowing for cell cycle progression 8• Once cdks become active, target proteins can 
then be phosphorylated on cdk consensus sites which leads to further cell cycle 
progression. 
As shown in figure 1, the predominate Gl cyclin/cdk complexes are cyclin 
D/cdk4/6 and cyclin E/cdk2. Following the activation of these complexes there is the 
further activation of the cyclin A/cdk2 in S phase and cyclin A/cdkl and cyclin B/cdkl in 
G2 and M phases 4 • Although cyclin D is expressed periodically unlike the other cyclins it 
is synthesized as long as the growth factor stimulation continues 9• 
Also shown in figure 1 are the two distinct families of cdk inhibitors (CKls) that 
have been discovered, known as the inhibitors of cyclin dependent kinase 4 (INK4) and 
the kinases inhibitor protein (KIP) families. The INK4 family consists of p151NK4, p161NK4, 
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p181NK4 and p191NK4, all of which specifically inactivate the Gl cdks which include cdk4 
and cdk6. These CKls form stable complexes with the cdk enzyme before the cydin can 
bind, preventing its association with cyclin D 10• The KIP family consists of p21 ciPi, p27KIPl 
and p57KIPl which binds and inhibits all cyclin/cdk complexes besides the cyclin D 
complexes 11• CKls are regulated both by internal and external signals, for example, the 
expression of p21 is under transcriptional control of the p53 tumor suppressor while the 
activation of p27 can occur due to transforming growth factor P (TGF-p), both 
contributing to the growth arrest of cells 12' 13• 
In terms of cell cycle regulation, the sole target phosphorylated by cyclin 
D/cdk4/6 is the retinoblastoma tumor suppressor (Rb) (Figure 1). During early Gl, Rb 
becomes phosphorylated and inactivated by cyclin D/cdk4/6 complexes, subsequently 
releasing the transcription factor E2F-1. This positively regulates the transcription of 
genes whose products are required for the progression into S phase such as cyclin E and 
cdc25 14• Once a cell reaches this state in late Gl, the cell is at a "point of no return", 
called the restriction point. Following this, the cell is committed to enter the cell next 
phase of the cell cycle and can't return back to Gl until a full cell cycle is completed. 
Importantly, limiting the amount of cyclin E available keeps cells inactive until a 
mitogenic signal intervenes. Cyclin E expression is dependent on E2F transcription 
factors once they have been released from Rb. When a cell is in the G0 quiescent state, 
Rb is in a hypophosphorylated state and bound to E2F. 
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Initially, these mitogenic signals as stated earlier, induce the expression of cyclin 
D and cdk 4/6 which then forms an active kinase state with p27 in order to 
phosphorylate Rb. This phosphorylation causes the dissociation of E2F from Rb which 
then transcribes cyclin E allowing for the formation of the active kinase cyclin E/cdk2. 
This newly formed cyclin E/cdk2 then works through a positive feedback loop to cause 
Rb to become hyperphosphorylated thus causing E2F to fully activate its target genes 
and induce the transition into S phase and DNA replication. 
1.2 Importance of p27K1P1 
As previously described, p27 is a key regulator of the Gl-5 phase transition. It 
serves to prevent premature activation of cyclin E/cdk2 in early Gl and also helps with 
the assembly and activation of cyclin D/cdk4/6 in late Gl. Therefore p27 can be thought 
as a positive regulator of Gl progression by this assembly and nuclear import of cyclin 
D/cdk4/6 11• It is now believed that the balance between the levels of cyclin Dl and p27 
are the main regulating mechanism for controlling proliferation of cells instead of their 
absolute levels within the cells 15• Nakayama et a/.(1996) discovered that p27 knockout 
mice develop multiorgan hyperplasia and parathyroid tumors which further supports 
the role of p27 in helping control cell proliferation and differentiation 16• 
The discovery of p27 was first shown by its inhibition of cyclin E/cdk2 and cyclin 
A/cdk2 in cells arrested by TGF-P and contact inhibition 17' 18' 19' 20• Specifically, p27 was 
shown to exhibit its inhibitory effect on cyclin E/cdk2 by binding to the catalytic cleft of 
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the complex, preventing it from phosphorylating Rb 21• Mitogenic growth factor signals 
have been shown to cause a loss of p27 levels and activity. In contrast p27 has been 
shown to increase in response to differentiation signals 22' 23' 24, loss of adhesion to the 
extracellular matrix 9' 25' 26' 27, and signalling by growth inhibitory factors such as TGF-~ 17' 
19, 20 
As cells exit Go and enter Gl, p27 that is bound to cyclin E initially must be 
degraded and newly synthesized p27 which is held within the cytoplasm helps facilitate 
the assembly and nuclear import of cyclin D/cdk. As described earlier, this cyclin D/cdk 
complex can then phosphorylate Rb in order to begin the transition into S phase. These 
effects in p27 are regulated by changes in its phosphorylation 28' 29 • It has been 
demonstrated that p27 mRNA levels do not change throughout the cell cycle but its 
protein levels are regulated by translational controls 22' 30 and also by ubiquitin mediated 
proteolysis 31• p27 is also predominately located within the nucleus in quiescent cells 
where it can act to inhibit cell cycle progression through the inhibition of cyclin E/cdk2 
32
• Pagano et al. (1995) demonstrated that p27 levels as well as its stability are high in 
quiescent cells and both fall during Gl to allow for activation of cyclin E/cdk2 and the 
progression into S phase 31• This decrease in p27 levels observed in the transition 
between G0 and S phase is due mainly to the dramatic decrease in its half-life which is 
six to eight times longer in the quiescent cells compared to proliferating cells 31• Another 
reason for the decrease in p27 can be attributed to the nuclear export of p27 following 
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Phosphorylation at 510 33• Therefore, changes in p27 levels are due to an increase in the 
degradation machinery rather.than an actual decrease in p27 transcription. 
1.3 Regulation of p27KIPl 
The mRNA_ expression of p27 as previously stated, does not change through the 
cell cycle but instead the protein content of p27 is regulated by stabilizing 
phosphorylation in G01 early Gl and inactivating phosphorylation in late Gl/ early S 
phase (Figure 2) 22' 30• 
Go Gl Gl Go Gl SRC LYN CD!K2 AKT 
MIRK hKIS/AKT YES ABL AKT CD'Kl A.MPK RSK1+2 
' 
\ 
' ' ' ' N· v Terminal Terminal 
' ' ' ' ' ' Go: Stability CDK2 Gl: Subcelluar Stability Go: Stability Gl: Subcellular actvity localization Gl: Subcellular 
localization localization & 
KPC mediated· Stability 
degradation 
Figure 2: Summary of post translational phosphorylation sites observed in p27 with 
known kinases that modify the individual sites as well as functions associated with 
these post-translational modifications. Modified from Vervoorts et al., 2008 
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As described, p27 acts on the catalytic cleft of cyclin E inhibiting its interaction 
with Rb but recently, three tyrosine residues (Y74,Y88 & Y89} have been ide:ntified 
within the middle of the p27 protein which are vital for its binding with cyclin E/cdk2 via 
hydrophobic interactions 21• Grimmler et al. (2007) discovered that these conserved 
tyrosine residues in the Cdk-binding domain of p27 can be phosphorylated by the 5RC-
family kinase and the oncogene product BCR-ABL in early Gl 21 • Once this occurs, the 
entire inhibitory helix of p27 is ejected from the cdk2 active site, thus partially restoring 
cyclin E/cdk2 activity. Once ejected, p27 undergoes other modifications which promote 
cytoplasmic localization, sequestration and/or proteolytic degradation 34• 
One of the initial modifications of the p27 nuclear pool after ejection is in 
response to mitogenic dependent stimulation, such as the mitogen-activated protein 
kinase (MAPK), which causes p27 to undergo nuclear export dependent on the 
phosphorylation at serine 10 (510) 33' 35' 36• Human kinase interacting stathmin (hKis) and 
Akt/PKB have been shown to phosphorylate p27 at 510 causing its translocation out of 
the nucleus and into the cytoplasm 4' 37• Due to this phosphorylation it has been 
discovered that p27 binds to the exportin CRMl in early Gl, allowing further Gl 
progression 33• Connor et al. (2003) discovered that p27 contains a nuclear export signal 
(NE5), and when mutated, causes a decrease in p27-CRM1 binding, nuclear export and 
p27 degradation 33• Once in the cytoplasm in early Gl, p27 is ubiquitinated and 
degraded by members of the KIPl-ubitquitylation promotion complex (KPC) 1 and 2 21' 34• 
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This initial degradation of p27 is necessary in order to promote the loss of p27 needed 
to activate the cyclin E/cdk2 located in the nucleus and promote S phase entry 4' 37• 
p27 proteolysis is regulated by a least two distinctly linked mechanisms wi,th one 
mechanism already addressed; the KPC complex. In early Gl, mitogens activate the 
export-linked degradation of p27 which is then followed in late Gl/S phase by the cyclin 
E/cdk2 dependent degradation. Phosphorylation of p27 occurs on the threonine 187 
(T187) by the newly assembled cyclin E/cdk2 complexes which targets the majority of 
p27 for ubiquitin mediated degradation 38• Phosphorylation of T187 allows p27 to be 
recognized by its SCF-type E3 ligase complex which is composed of Skpl, Cull, ROCl and 
the F-box proteins Skp2 which mediates p27 ubiquitylation and degradation by the 265 
proteasome 39' 40' 41• Skp2 is the component of the F-box protein in the SCF-ubiquitin 
ligase that is responsible for p27 proteolysis in late Gl. 
Both of these independent mechanisms of p27 degradation are necessary in 
order to promote the loss of p27 needed in order to enter S phase. As a whole, the 
initial mitogen stimulation and subsequent export linked KPC degradation of p27 allows 
for the incremental activation of cyclin E/cdk2 which is followed by rapid cdk2 activation 
and T187 phosphorylation dependent degradation of p27 allowing S phase entry (Figure 
3). Skp2 has been shown to cause the ubiquitin mediated degradation of approximately 
80% of all p27 while the initial degradation of p27 due to KPC accounts for the other 
20% needed for cell cycle progression (Figure 3) 32' 42 • 
11 
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Also important is another phosphorylation event that occurs on newly translated 
p27, occurring on threonine 157 (T157), phosphorylated by PKB/ Akt 33• By 
phosphorylating p27 at T157, this newly synthesized p27 is unable to be imported into 
the nucleus and is localized within the cytoplasm. As shown in figure 2, within the p27 
nuclear localizing signal (NLS) there contains an Akt consensus site at T157 and once 
phosphorylated, it impairs p27 translocation to the nucleus. This is due to an interaction 
with the 14-3-3 proteins, a family of conserved regulatory molecules, that cause the 
T157 phosphorylated p27 to become sequestered in the cytoplasm 43 • Shin et al. (2005) 
discovered that 510 phosphorylation and CRMl export can lead to Akt further 
phosphorylating p27 in the cytoplasm at T157 and the 14-3-3 protein family then 
impairs its interaction with importin-a 43 (Figure 3). 
12 
Cytoplasm 11 Nucleus 
~·· • 
hKis/Akt cdk2 
• •• 
Figure 3: Summary of p27 degradation and translocation mechanisms. 
Phosphorylation sites on p27 with effects of hKis/ Akt {510), cdk2 (T187} and Akt 
(T157). 
Not all phosphorylation sites on p27 cause ubiquitin-mediated degradation 
and/or nuclear export, as some facilitate p27 effects on cell cycle arrest and protect it 
from these events 44• The most significant stabilizing phosphorylation to p27 is caused by 
AMP-activated protein kinase (AMPK} on threonine 198 {T198} 45' 46• This stabilizing 
phosphorylation is important in quiescent and early Gl cells as this T198 
phosphorylated p27 inhibits cyclin E/cdk2 leading to cell cycle arrest. Liang et al. (2007) 
discovered that in MCF7 cells, activated AMPK {pAMPK) directly phosphorylated p27 on 
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T198 (T198p27) 45• This then causes cell cycle arrest by increasing the stability of the 
protein. Also interesting to note is that Rattan et al. (2005) demonstrated that AICAR; an 
AMP analog which can indirectly up-regulate AMPK through its upstream kinase, liver 
kinase Bl (LKBl), increases pAMPK, stabilizes p27 and p53 47• AICAR also inhibited the 
Akt pathway through its upstream activator phosphatidylinositol-3-0H kinase (Pl3K), 
which when taken together, caused 70-80% of MCF7 breast cancer cells to undergo 
growth arrest in S-phase 47• Phosphorylation on T198 increases total p27 protein half-life 
when compared to T198 mutated p27 cells when activated with AICAR 45• The 
importance of this stabilizing phosphorylation on p27 is extremely important to cell 
cycle arrest and required for optimal cell cycle progression. As will be outlined in the 
next sections, alteration of one or more of these phosphorylation events on p27 can 
lead to the cell no longer being under proper cell cycle control, leading to uncontrolled 
proliferation and cancer. 
1.4 Deregulation of the Cell Cycle in Cancer 
The orchestration of the Gl/S phase transition is elaborate and it is not 
surprising that several components of this transition can become involved in the 
progression of cancer. The Gl/S transition does not constitute the only cell cycle 
transition that has been implicated in the development of cancer but many of the cell 
cycle events which are necessary for controlled proliferation have been found to be 
altered, specifically in breast cancer 4• Many direct cell cycle oncogenes such as cydin D 
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and cyclin E have been found to be no longer under proper function/control in many 
breast cancer cases as well as the tumor suppressor proteins (TSP) pRb, p53 and p27 4• 
Cyclin Dl has been discovered to be over expressed with or without gene 
amplification, in over 50% of breast cancers but is more prominent in estrogen receptor 
positive (ER+) breast cancers 48• It has been found that cyclin Dl is required in order for 
mammary tumor formation by the Ras pathway, a small GTPase that acts as a potent 
mediator of cell growth and survival signals 49 • In early/late Gl as mitogenic signals 
cause an increase in Ras which in turn increases the production of cyclin D to further 
advance the cell cycle. These mitogenic signals, acting through different receptor 
tyrosine kinases or G-protein coupled receptors can not only activate Ras but also the 
Pl3K pathway in order to stimulate cell proliferation and survival. Pl3K promotes cell 
survival by means of Akt up regulation as it aids cdk activation by relieving two arresting 
constraints of the cell cycle. As previously described, Akt can phosphorylate p27 at both 
T157 and SlO, which causes the nuclear export and ubiquitin mediated degradation of 
p27, respectfully. Secondly, Akt can also phosphorylate {S9) and inactivate glycogen 
synthase kinase 3P (GSK-3P) which acts to both directly and indirectly inhibit cyclin D 50 • 
GSK-3P achieves this inhibitory role on cyclin D by phosphorylating it at T286 causing its 
nuclear export and degradation 51• Also, cyclin D can be inhibited indirectly by GSK-3P 
which has been shown to phosphorylate the transcription factor c-Myc at T58, causing it 
to become destabilized 52• c-Myc induces the transcription of cyclin D as well as cyclin E 
and so GSK-3P can indirectly inhibit both cyclin proteins by inhibiting the upstream 
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transcription factor c-myc 53• Also c-myc has also been found to be over expressed in 
over 50% of breast tumors and therefore losing control of c-myc leads to increased risk 
of breast cancer 54 • Stabilization of c-Myc is achieved by phosphorylation on S62 by 
MAPK which is a downstream effector of Ras 55• All of these activations or inactivations 
of both Ras and c-Myc are shown in figure 4 . 
. ~ Pl3K----> Akt-1 GSK-3(3 Ras ,,-~ I _ 
'- - sG2 --1..2.58 Cyclin D/cdk4 ·~ MAPK 1 ;.. c-Myc - ..... :
I Cyclin E/cdk2 
Figure 4: Summary of Ras and c-Myc activation and inactivation. Constituently active 
Ras or c-Myc can cause increased expression of cyclin D/E, leading to increased 
proliferation and tumor development. 
The F-box protein Fbw7 is part of the SCF-ubiquitin ligase complex responsible 
for the ubiquitin mediated degradation of Ras, c-Myc abd cyclin E 56• The loss of Fbw7 in 
some breast cancers leads to c-Myc activation and cyclin E stabilization which both 
promotes cell proliferation 56• Therefore in many ca.ncers, the over expression and/or 
amplification of either Ras or c-Myc can cause increased proliferation and cell cycle 
entry by increasing cyclin D and E. This increased activity of the Gl/S phase cyclins 
promote this phase transition and can lead to tumor progression. 
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1.5 Deregulation of p27K1P1 in Cancer 
The TSP p27 is an important protein in cancer development and progression. 
Although p27 mutation is rare, loss of a single p27 allele occurs in some human 
malignancies, however silencing of the remaining allele is rare 57• Most p27 dependent 
tumor issues occur thorugh accelerated proteolysis or cytoplasmic mislocalization. As 
stated in the previous section, increased Ras expression can cause an increase in Akt 
which in turn can increase both its proteolysis and cytoplasmic localization. This 
reduction in p27 protein levels has been shown in up to 60% of all cancers including 
breast 38• 
p27 protein levels as well as localization appear to have prognostic significance 
in breast cancer. Strong p27 immunostaining has been shown in the nuclei of normal 
human mammary duct epithelial cells but a loss of p27 protein has frequently been 
demonstrated in breast cancer 58• Tan et al. (1997) demonstrated that patients with 
breast cancer and less than 50% of p27 within the nucleus using immunohistochemical 
staining, was an independent prognostic factor with a 3.4 fold increased risk of death 59 • 
This study was using older women with the mean age of 60 but this trend of decreased 
nuclear p27 resulting in a lower survival rate also has been shown in younger women. In 
a study by Porter et al. (1997), it was observed that in breast cancer pateints under the 
age of 45, decreased p27 is a predictor of poor overall survival using multivariate 
analysis 60• They also looked at cyclin E and found that patients with tumors that 
displayed both low p27 protein and elevated cyclin E protein had the highest mortality 
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• As one would expect, breast tumors with low p27 have been shown to also have high 
cyclin E/cdk2 activity 61 • A reduction in p27 has been found in premalignant and 
noninvasive ductal carcinoma in situ (DCIS), therefore appearing to precede the 
development of breast cancer invasion and progression 62' 63 • Gillett et al. (1999) 
discovered that patients with higher nuclear p27 expressing tumors had a significant 
longer relapse period and overall survival compared to those who had low nuclear 
expressing p27 tumors 15• Also it was found that at 5 years, 80% of the patients with high 
p27 expressing tumors were alive compared to only 50% of the patients with low p27 
expressing tumors. Another study by Chappuis et al. (2000) showed that women with 
node negative breast cancer and reduced nuclear p27 was associated with a 10-fold 
increase in the risk of cancer relapse 64• 
The localization of p27 is extremely important in determining cancer progression 
and overall possible survival. Tumors that retain abundant p27 are found to often show 
p27 mislocalization within the cytoplasm away from its nuclear cyclin/cdk targets. It has 
been reported that p27 has been found to be mislocalized within the cytoplasm in up to 
40% of primary human breast cancers 65' 66' 67 • The best outcome for a breast cancer 
patient exist when there are high levels of exclusively nuclear p27, while the worst were 
those with reduced p27 levels as well as cytoplasmic localization 66• In all cases with 
cytoplasmic p27 localization it has been significantly associated with Akt activation 65' 66• 
The oncogenic activation of the Pl3K/ Akt pathway causes the Akt dependent 
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phosphorylation of p27 and presents an important mechanism underlying the 
cytoplasmic mislocalization in human cancers. 
2. Obesity 
The prevalence of obesity has been on the rise for the past 20 years and has 
more than doubled since 1980. More than 1.4 billion people worldwide are considered 
overweight and of that 500 million are considered obese 68• Obesity can now be 
classified as an epidemic as these numbers are predicted to continue to rise. 
In order to determine an individual's weight status, a worldwide index, known as 
the body mass index (BMI) is often used to classify adults as overweight and obese. The 
BMI is a simple weight to height calculation (kg/m2) in which an individual with a 
BM1>25 is considered overweight, while a BM1>30 is considered obese. BMI provides the 
most useful population level measure of overweight and obesity as it is the same for 
both sexes and all ages of adults. It is important to note that it is just a rough guideline 
and does not equate the same level of "fatness" in all individuals. One fundamental flaw 
of BMI is it does not tell you where the fat is located. Increased obesity, particularly in 
the visceral {intra-abdominal) compartment, has been found to be associated with many 
negative health issues such as insulin resistance, hyperglycemia, dyslipidemia and 
hypertension 69• 
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Obesity in its simplest form can be thought as a prolonged state of positive 
energy balance. This may be due from excess dietary caloric consumption and or 
insufficient caloric expenditure though physical inactivity. Due to this net positive 
balance, energy in the form of triglycerides is stored inside specialized fat cells known as 
adipocytes until the body requires increased substrate for energy production. Obesity is 
characterized by on part an excess accumulation of white adipose tissue (WAT) which is 
primarily composed of adipocytes, fibroblast, macrophages, stromal cells and 
endothelial cells 70• 
Adipose tissue is also a major site for the production of estrogen in obese 
postmenopausal women, most notably in tissues of the breast, abdomen, thighs and 
buttocks 71 • Estrogen biosynthesis is catalyzed by the enzyme aromatase (aromatase 
cytochrome P450) and obese postmenopausal women have been found to have 
increased adipose-dependent production of estrogens 72 • 
2.1 Link Between Obesity and Breast Cancer 
From decades of research we now know that individuals who are considered 
obese (BMl>30) have been found to have the greatest health risks compared to their 
lean counterparts. An increased BMI is a risk factor for non-communicable diseases such 
as type 2 diabetes, cardiovascular diseases (heart disease, stroke), as well as some 
cancers including breast and prostate 73' 74• 
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For over 40 years researchers have found a statistical association that an 
increase in adiposity is correlated with an increased risk of cancer 75• In 2007, reports 
from the American Institute for Cancer Research and the World Cancer Research Fund, 
predict that in 10 years obesity will overtake smoking as the leading cause of cancer 76• 
Obesity causes an increased risk of breast cancer in postmenopausal women that is 30-
50% greater than their lean counterparts 77• Not only is the incidence higher in obese 
women but the death rate is also higher. A recent study by Calle et al. (2003), 
discovered that obese postmenopausal women in the highest quintile of BMI had 
double the death rate (relative risk, 2.12) from breast cancer compared to 
postmenopausal women in the lowest quintile of BMI 74 • Obese breast cancer patients 
seem to have a higher risk for lymph node metastasis, larger tumors and death when 
compared to non-obese breast cancer patients 78• In a meta-analysis by Harvie et al., 
(2003), they calculated a 39% lower risk of breast cancer in postmenopausal women 
with the smallest waists compared with those who had the largest waists and a 34% 
lower risk of breast cancer in postmenopausal women with the smallest waist-to-hip 
ratio (WHR) compared with those who had the highest WHR 79• Premenopausal women 
also show an increase in breast cancer incidence with increases in visceral obesity while 
general obesity causes these increases when comparing postmenopausal women. 
Premenopausal women with invasive ductal breast cancer have been shown to have a 
higher mortality rate (relative risk, 2.50) if they were in the highest quartile of BMI 
compared to women in the lowest quartile 80• Independent of menopausal status, obese 
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women are more likely to suffer from metastatic breast cancer and have a poorer 
clinical outcome than non-obese women. These observations cannot be fully explained 
by alterations in sex hormone levels (estrogen) alone and therefore must be mediated 
by another mechanism. 
There are theories as to the molecular mechanisms underlying this statistical link 
between obesity and breast cancer, with newer hypothesis placing adipocytes and their 
autocrine and endocrine functions at the forefront. Initially adipocytes were believed to 
be inert storage depots but we now know that they are highly active endocrine cells that 
secret many factors including growth factors, cytokines, extracellular matrix proteins 
and hormone like molecules known as adipokines 81' 82' 83• These adipokines can act in an 
endocrine fashion via the peripheral circulation or in a more direct paracrine method, 
binding to their respected membrane receptors on the surrounding epithelial cells. As 
shown in figure 5, adipokines which are produced and secreted by the adipose tissue 
can enter the interstitial space and follow either two paths. 
The adipokines can enter the blood stream, acting on distant targets of the body 
as an endocrine factor. They can also signal locally, binding to their respective 
membrane receptor of immediate surrounding tissue acting as a paracrine factor. This 
paracrine signalling is important to note as adipocytes make up the bulk of breast tissue 
and represent one of the most abundant cell types surrounding mammary epithelium. 
This could therefore play a large part in the stromal-ductal epithelial cell interactions 
within the mammary microenvironment 84• This is important as many primary breast 
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tumors originate from ductal or intraductal epithelial cells. It is still not entirely clear 
how adipocytes influence breast tumor cell behaviour or whether any of the paracrine 
factors (adipokines) secreted by these adipocytes can change the phenotypic behaviour 
of malignant cells. 
Figure 5: An example of how adipokines can be· produced and secreted into the 
interstitial space where they can either act on a larger body wide scale through 
endocrine signalling or can act locally or surrounding microenvironment though 
paracrine signalling 
2.2 Adipokines as Circulating Hormones in Breast Cancer 
To date there have been over 50 different adipokines discovered that are 
produced and secreted by adipocytes. These adipokines are involved in metabolic 
functions including insulin sensitivity, glucose metabolism and fatty acid oxidation as 
well as contributing to protein synthesis and cell proliferation 85' 86' 87• With such a large 
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number of possible factors which possibly influence breast cancer development, two 
adipokines, namely adiponectin (ADIPO) and leptin (LEP) have come to the forefront of 
research. 
One reason for this focus is that both ADIPO and LEP are the most abundant 
adipocytokines produced almost exclusively by adipocytes and have also both been 
shown to affect the growth status of cells. Specifically, both ADIPO and LEP have been 
shown to be involved in regulating the proliferation of breast cancer cells, both in cell 
culture and in-vivo 84• Interestingly, ADIPO and LEP effects on both metabolism and cell 
proliferation act as antagonists to one another 84' 88' 89 • LEP synthesis and plasma levels 
are increased with obesity and higher LEP levels have been significantly asso~iated with 
increases in breast cancer incidence 90' 91• Interestingly, LEP has also been shown to 
stimulate aromatase expression in MCF7 breast cancer cells which would help promote 
cell growth and cycling by converting androgens to estrogen 92• ADIPO on the other 
hand, has the opposite effect, as levels in the serum decrease with increased obesity 
and an inverse relationship between serum ADIPO levels and breast cancer risk has 
been reported 93• In a study observing Taiwanese breast cancer patients, Chen et al. 
(2006) discovered that the serum LEP:ADIPO ratio was significantly increased in breast 
cancer patients when compared to control patients without breast cancer 94• Previous 
research has shown that the ratio between ADIPO:LEP is altered as a women becomes 
obese. The ratio calculated shows that lean women have an ADIPO:LEP ratio of 1588:1 
while obese women show a significantly lower ratio of 163:1 95.The status of the 
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estrogen receptor, HER2/neu or lymph node metastasis did not affect serum LEP or 
ADIPO levels in breast cancer patients and after adjusting for confounding factors, 
serum LEP and ADIPO levels were positively (r=0.323, P=0.001) and negatively (r=-0.333, 
P=0.001) correlated to BMI, respectively 94 • Figure 6 illustrates how the ratio between 
ADIPO and LEP shifts as an individual increases or decreases the size of adipose depots 
within the body. 
LE PT IN 
ADIPONECTIN 
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Figure 6: Relationship between ADIPO:LEP in lean and obese individuals. A lean 
individual has a higher ratio of ADIPO:LEP. As this individual becomes obese, the size 
and number of adipocytes increases while the ratio of ADIPO:LEP decreases. The ratio 
between ADIPO:LEP is key and not the absolute concentrations of adipokines. 
2.3 Leptin (LEP) 
LEP is a product of the obese (ob) gene and is a 16 kDa cytokine which was 
discovered in 1994 that acts through the hypothalamus as a regulator of body weight 
and energy balance 96• This is achieved by inhibiting food intake and increasing energy 
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expenditure. In animals which have mutations in the gene encoding LEP, morbid obesity 
is observed. However, in humans these mutations very rarely occur and obesity is 
related to LEP resistance instead of LEP deficiency 97' 98' 99 • LEP mRNA has been primarily 
detected in both WAT and BAT, as well as a number of non-adipocyte tissues which 
synthesize and secret LEP, such as mammary epithelial cells 100• The major factor which 
influences plasma LEP concentrations is the amount of adipose mass in humans. 
Circulating levels of LEP have shown a strong positive correlation with total body fat and 
a lesser degree with BMI 101, 90• One important discovery was that serum LEP levels are 
significantly higher in women compared to men, even after adjusting for total body fat 
mass 102• The negative effects of LEP can be lessened by caloric restriction and weight 
loss, since these cause circulating LEP levels to decline rapidly 103• 
2.4 LEP Signaling and Cancer 
LEP exerts its biological effects through binding to its membrane receptors. 
Several different receptors isoforms exist including the long form (Ob-Rb) as well as the 
short form (Ob-Ra) 104• 105• Only the full length Ob-Rb has full signaling capabilities, 
whereas the short Ob-Ra lack major domains that are needed to recruit downstream 
effectors. Both the long and short isoforms of LEP have been discovered in the human 
breast cancer cell lines MCF7, T47D and MDA-MB-435 106• 107• 
Upon LEP stimulation, intracellular Janus tyrosine kinases (JAK2) are activated 
through transphosphorylation and phosphorylate tyrosine residues on the long isoform 
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LEP receptor and also on signal transducers and activators of transcription (STAT) 
proteins 108• These phosphorylated STAT proteins can then dimerize and translocate to 
the nucleus where they activate numerous genes including those involved .in cell 
proliferation. Also, LEP signaling through Ob-Rb has also been shown to activate the 
Ras/MAPK pathway as well as the Pl3K/ Akt pathway 109' 110• From our cell cycle review 
we know that Ras/MAPK and Akt all increase cell cycle proliferation by affecting p27 
localization or stability. Figure 7 shows the LEP signaling pathway and the events 
produced when bound to its transmembrane receptor Ob-Rb. LEP signaling has been 
shown to crosstalk with both polypeptide growth factor signaling and also with steroid 
receptor function. An example of this is how insulin can cause an increase in LEP 
expression but an increase in insulin can also lead to LEP resistance by inhibiting LEP 
signaling through JAK2, by the suppressor of cytokine signaling (SOCS3) 111' 112• This 
occurs as LEP accumulates in the serum, binds to its receptor and activates the 
JAK2/STAT3 pathway. STAT3 can then dimerize and translocate to the nucleus where it 
upregulates the negative feedback gene SOCS3 which inhibits JAK2 111' 112 • Although this 
LEP resistance can shut off the JAK2/STAT3 pathway, LEP signalling has been shown to 
continue affecting downstream proteins such as p27 even when the JAK2/STAT3 
pathway is inhibited 113• Therefore LEP appears to exhibit its cell cycle effects through 
another signaling pathway other than JAK2/STAT3, possibly the Pl3K/Akt pathway. Also, 
LEP has been shown to enhance the stability of estrogen receptor a (ERa), which leads 
to maintenance of ER-dependent transcription in breast cancer cells, even in the 
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presence of antiestrogens 101• All of these events are important in the development of 
breast cancer and to the understanding of why obese postmenopausal women are at 
such as an increased risk for breast cancer development. 
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Figure 7: LEP receptor signaling. Showing how Ob-Rb stimulates a broad spectrum of 
intracellular signaling pathways. LEP stimulates both Akt and Ras/MAPK, both of 
which cause cell growth and proliferation by inhibiting cell cycle inhibitors p27K1P1, Rb 
and p53. All of which once down regulated or inhibited cause cancer progression. 
STAT3 can also translocate into the nucleus and induce the transcription of genes 
including SOCS3 which acts as a negative feedback mechanism for JAK2. 
LEP has been shown to act as a mitogen, transforming factor or also a migration 
factor for many different cell types including both normal and malignant mammary 
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epithelial cells 106• Ishikawa et al. (2004) found that LEP was overexpressed in 92% of 
examined breast carcinomas but was absent when observing normal breast epithelium 
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• LEP has been discovered to induce cell cycle progression by upregulating cdk2 and 
cyclin Dl levels, both of which have been found to be upregulated in many breast 
cancers and force the Gl to S phase transition 115' 116• In a study by Yin et al. (2004), it 
was shown that LEP increases both cyclin Dl/E by stimulating the expression of c-Myc 
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• Saxena et al. (2007) showed that treating MCF7 cells with LEP caused an increase in 
the number of cells which had entered S phase and a decrease in the number of cells 
which were still in G0/Gl while also showing that LEP stimulated the growth of MCF7 
cells in both a time and dose dependent manner 118• From these studies it can be 
theorized that LEP causes an increasing in certain key components of the cell cycle 
machinery such as cyclin D/E possibly through an upregulation c-Myc. Through these 
affects as well as the decrease in certain key cell regulation proteins such as p27K1P1, LEP 
is able to promote a positive growth environment of breast cancer cells possibly 
explaining why obese individuals have a higher incidence of breast cancer. 
Interestingly if LEP is taken out of the equation, there is a clear decrease in 
cancer development. Cleary et al. (2004) showed that obese mice genetically deficient in 
the long isoform of the LEP receptor Ob-Rb (Lep/bLep/b) and overexpressing the 
oncogene TGF-a actually do not develop oncogene induced mammary tumors 119• This 
suggest that in the absence of LEP, obese mice have a reduced risk of developing 
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oncogene induced mammary tumors, further stressing the importance of LEP in cancer 
development and progression. 
2.5 Adiponectin (ADIPO) 
ADIPO is a 30 kDa adipocytokine which has been identified to be secreted 
primarily by white adipocytes and is abundantly present (2-20 µg/ml) in human plasma. 
Serum levels of ADIPO have been shown to be strongly inversely correlated with waist 
circumference and visceral fat; even more so than BMI 120• ADIPO has also been found to 
have anti-inflammatory and anti-diabetic functions as well as suppression of the process 
of angiogenesis 121• 
There are several different forms of ADIPO within the plasma that are capable of 
binding with varying affinity to ADIPOs receptors. Full length ADIPO exists as either a 
trimer known as low molecular weight (LMW), or as two larger multimers known as 
medium molecular weight (MMW) and high molecular weight (HMW) forms 122• ADIPO 
can also be cleaved and exist in the serum as a smaller globular fragment known as 
globular ADIPO (gADIPO) 123• The different free forms of ADIPO have been detected 
within human plasma and have been found to bind to the two ADIPO receptors with 
differing affinities, which then initiate the downstream effects observed by ADIPO 
stimulation. 
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2.6 ADIPO Signaling and Cancer 
Two ADIPO receptor forms (ADIPORl and R2) have been cloned and shown to 
have unique distributions throughout the body and altered affinities for the different 
forms of circulating ADIPO 124• Both receptors share a 67% sequence homology and 
represent the only two ADIPO receptors that have been identified to date. ADIPORl and 
R2 have been shown to exist as integral membrane proteins with an internal N-terminus 
and an external C-terminus 124• This is of course opposite to the topology which is 
observed in G protein-coupled receptors. 
gADIPO has been shown to have the highest affinity for ADIPORl 124, while 
ADIPOR2 has been shown to have intermediate affinity for both globular and full length 
ADIPO 125• ADIPORl has been found to be most abundantly located in skeletal muscle 125, 
but has also been found present in healthy breast epithelial cells 126, in both invasive and 
pre-invasive breast cancer tissue 127 and in human adipocytes 128• ADIPOR2 has been 
found located mainly in the liver while low amounts have been found in other tissue 
locations 125• Important to note is that ADIPORl protein and mRNA have been detected 
in many primary breast cancer cell lines including MCF7, T47 and MDA while ADIPOR2 
expression was found to be much lower 129' 130• Furthermore, Rasmussen et al. (2006) 
have shown that ADIPORl mRNA expression is 10-15 times higher than ADIPOR2 in 
human isolated adipocytes 128• Therefore, in my thesis ADIPORl functioning will be 
investigated exclusively due to its higher localization in both breast cancer cells and 
adipose tissue then ADIPOR2. 
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ADIPORl has been shown to mediate fatty-acid oxidation and glucose uptake 
once stimulated by ADIPO through the downstream phosphorylation-dependent 
activation of AMPK 131• The activation of AMPK occurs when there is an increase in the 
AMP:ATP ratio. This increase in AMP then allows for AMP to bind to the v Bateman 
domain causing a conformational change in AMPK exposing its catalytic domain on the a 
subunit 132• With its catalytic domain exposed, the upstream AMPK kinase (AMPKK) can 
then phosphorylate AMPK at threonine 172 (T172) causing it to become active 132• 
ADIPO is able to not only activate AMPK and elicit its downstream metabolic effects, but 
this activation of AMPK also has been found to have cell cycle effects. AMPK has been 
shown to be phosphorylated (pAMPK, T172) with ADIPO stimulation in breast cancer 
cell lines, including MCF7, T47D and MDA-MB-231 126' 129' 133' 134• MCF7 cells treated with 
ADIPO were found to undergo both a time- 135' 134 and dose-dependent inhibition of 
proliferation 136• ADIPO induces similar activation of pAMPK to that seen when MCF7 
cells are incubated with AICAR, which causes an increase in the AMP analogue ZMP 
which then alters the ZMP:ATP ratio causing AMPK activation 129' 134• From previous 
research in our lab in 2007, a study by Walker et al. found that increasing 
concentrations of ADIPO caused an increase in p27 while in contrast LEP showed a 
decrease in p27 protein 113• This is important as the AMPK pathway assists in the 
stabilization of the cell cycle inhibitor p27 via a phosphorylation on threonine 198 
(T198p27). AICAR has been shown to cause AMPK-dependent cell cycle arrest in a dose-
dependent manner in many cancer cell lines including MCF7 cells. This in turn has been 
32 
shown to increase the amount of cells arrested in S-phase, inhibit the Pl3K-Akt pathway 
and up-regulate the cell cycle regulator proteins p27 and p53 47• Besides inhibiting the 
Pl3K/ Akt pathway, ADIPO has also been shown to decrease the activation of MAPK as 
well as decrease the mRNA expression of cyclin Dl and c-Myc 129• This is of course 
opposite to the affects observed in cell treated with LEP. The antagonism between the 
two adipokines and their effects on the cell cycle are determined by the amount of each 
within the serum, which favours LEP and cell proliferation in obese individuals. ADIPO 
may also inhibit the activation of nuclear factor-KB {NF-KB), a transcription factor which 
has been found to upregulate the pro-angiogenic factor vascular endothelial growth 
factor (VEGF) in breast cancer cells 137• Figure 8 shows a simplified depiction of the 
ADIPO and AMPK activation in normal and malignant cells. 
From these studies we can observe that ADIPO causes an increase in pAMPK and 
a decrease in pAkt yet the mechanisms are unclear. Kim et al. (2009) uncovered that 
ADIPO treatment increased pAMPK (Thr 172), which caused the dephosphorylation of 
Akt (Thr 308 and Ser 473) in MDA-MB-231 breast cancer cells by increasing protein 
phosphatase 2A (PP2A) activity 134• The dephosphorylation of Akt by ADIPO was blocked 
once the AMPK inhibitor, Compound C was added to the ADIPO treatment while the use 
of a PP2A inhibitor, okadaic acid, caused all pAMPK effects on pAkt to be abolished. This 
indicates that AMPK working through PP2A could be causing the decrease in pAkt in 
MDA-MB-231 cells. Although this pathway has yet to be confirmed in MCF7 cells, it may 
be possible that ADIPO causes an increase in pAMPK, which in turn causes an increase in 
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T198p27 and a decrease in pAkt, both which would cause a decrease in cell 
proliferation. 
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Figure 8: ADIPO and AMPK signaling. The energy sensing kinase AMPK is activated by 
ADIPO as well as by exercise and pharmacological agents. Once activated, AMPK 
phosphorylates and stabilizes p27 leading to cell cycle arrest in both normal and 
malignant cells. 
2. 7 Importance of ADIPO and ADIPORl 
As ADIPO has been shown to affect both pAMPK and the Pl3K/ Akt pathways, it is 
again not surprising that any alteration to ADIPO serum concentration or ADIPORl 
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expression can lead to possible cell cycle problems. Mantroros et al. {2004) found an 
inverse relationship between circulating ADIPO levels and breast canc:er in 
postmenopausal women which was independent of possible effects of insulin growth 
factor (IGF-1), LEP, BMI and other parameters 138• 
ADIPORl gene expression was also found to be 62% lower in obese women 
compared to lean women in omental adipose tissue and 60% lower in subcutaneous 
adipose tissue 128• In addition, the consumption of very low calorie diets (VLCD) 
sustained for 8 weeks with an average weight loss of 12.lkg was shown to increase 
expression of adipoRl in subcutaneous adipose tissue by 80% and an increase 
expression of ADIPO in adipose tissue by 65% in humans 128• Therefore, it can be 
theorized that a decrease in adiposity can increase the amount of ADIPORl leading to 
better utilization of existing ADIPO. This is important for obese women as there will be 
a decrease in ADIPO and ADIPORl while an increase in LEP, all of which have been 
shown to produce a positive growth environment. 
At the present time, it is still unclear exactly how obesity plays a role in 
decreasing ADIPORl and how both the adipokines ADIPO and LEP play a role in this 
effect. The effects of ADIPO on cell cycle arrest have been shown but the effects that 
the adipokine has on ADIPORl are still to be uncovered. Examining the role of ADIPORl 
signalling and functioning in breast cancer cells I believe, may play an intricate role in 
the negative effects which are observed in obese breast cancer patients and the positive 
protective effects observed in lean individuals. Therefore, my thesis will look at the role 
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ADIPORl signaling plays in cell cycle regulation as well as how the receptor responds in 
an obese environment and how this plays a role in the regulation of proliferation in 
breast cancer cells. 
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3. Study Objectives 
1. To determine the effects of the adipokines ADIPO and LEP on ADIPORl protein 
expression and downstream signaling molecules in MCF7 breast cancer cells. 
2. To determine if an upregulation of ADIPORl in MCF7 cells can counteract the 
negative effects on cell cycle proteins observed with LEP and in co-culture with 
obese adipocytes. 
3. To determine if any difference occurs between a chow diet (CD) and a high fat 
diet (HFD) in rats causes changes in adipocytes and ADIPORl protein content in 
both non-transfected MCF7 cells and ADIPORl transfected cells. 
4. Hypothesis 
1. LEP causes a decrease in ADIPORl through an upregulation of pAkt in MCF7 cells. 
2. The ratio between ADIPO:LEP (rather than the absolute concentrations of each 
adipokine) is important to the stability of ADIPORl 
3. The 14-3-3 protein plays a protective role in ADIPORl protein stability protecting 
it from LEP induced destruction. 
4. Upregulating ADIPORl protein expression in MCF7 cells will lessen the negative 
effects on cell cycle entry with LEP treatment, while increasing the cell cycle 
inhibitory effects of ADIPO treatment. 
5. Adipocytes from HFD rats will deregulate the cell cycle in MCF7 cells and these 
effects will be tempered by overexpressing ADIPORl. 
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5. Materials and Methods 
Cell Line and Cell Culture. The human breast cancer cells, MCF7, were obtained 
from a pleural effusion and purchased from the American Tissue type Culture Collection 
(ATCC, Manassas, VA). These cells were maintained routinely in Alpha Modification of 
Eagle's Medium (AMEM, Wisent, St.Bruno, QC), 10% fetal bovine serum (FBS, Hyclone, 
Thermo Fisher Scientific, Whitby, ON), 2% anti-micotic/anti-biotic (Wisent), 1% lOOmM 
sodium pyruvate (Sigma, Oakville, ON), 1% non-essential amino acids (Sigma), and 10 
µg/ml insulin from human pancreas (Wisent) at 37°C and 5% C02• For arrested 
experiments, the cells were plated in AMEM for 48 hours, then media was aspirated, 
and the cells were washed twice with phosphate buffered saline (PBS, Wisent) and 
maintained in Improved Modification of Eagle's Medium without phenol red (IMEM, 
Wisent), 2% dextran-charcoal treated fetal bovine serum (c-FBS, Hyclone, Thermo Fisher 
Scientific, Whitby, ON), 2% anti-micotic/anti-biotic(Am/Ab) for 48 hours at 37°C and 5% 
C02. 
Cell Growth. MCF7 cells were plated in 6 well plates in AMEM for 24 hrs. At 
approximately 70% confluence, cells were either maintained in AMEM (cycling 
experiments) or IMEM (arrested experiments) and treated with various concentrations 
(3-24 nM) of human globular ADIPO (Peprotech, Rocky Hill, NJ), or (25-200 nM) of 
human recombinant LEP (Peprotech) for 24 hrs. In co-culture experiments, cells were 
exposed to concentrations of either ADIPO (9 or 18 nM) or recombinant LEP (150 or 300 
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nM) for 24 hrs. The use of a pharmacological Akt inhibitor (1L6-Hydroxymethyl-chiro-
inositol-2-(R)-2-0-methyl-3-0-octadecyl-sn glycerocarbonate, EMO-Millipore, Bi:llerica, 
MA) was used to look at Akt involvement in cell cycle signalling using various 
concentrations (1-10 nM) of the Akt inhibitor for 24 hrs. DMSO was added to cells not 
treated with Akt inhibitor as a vehicle control. In immunoprecipitation experiments, 
additional pharmacological treatments were done including estrogen (10 nM, Sigma), 
the AMPK agonist AICAR (5-Aminoimidazole-4-carboxamide-1-~-D-ribofuranoside, lmM, 
Toronto Research Chemicals, Toronto, ON) and the AMPK inhibitor Compound C (AMPK 
inhibitor, lmM, Millipore) 
Cell Harvesting. The 6 well plates were aspirated to remove media and washed 
twice with cold PBS. Cells were collected using a 25 cm cell scraper and transferred into 
1.7 ml Eppendorf tubes with 1 ml of cold PBS. Cells were centrifuged at 2300 ref at 4°C 
for 10 minutes. The supernatant was discarded and the pellet was then re-suspended in 
TENT++ (0.2% Tent [TRIS, EDTA, NaCl, and 0.2% Triton x-100], Sigma protease inhibitor 
cocktail and Sigma phosphatase inhibitor cocktail 2). Samples were then sonicated for 5 
seconds at 10% power and centrifuged for 10 minutes at 15700 ref. The supernatant 
lysate was then extracted and stored at -84°C. 
Western Blotting and lmmunoprecipitation. The activation of ADIPO and lEP 
signalling pathways as well as expression of ADIPORl and p27K1P1 were assessed by 
Western blotting or immunoprecipitation followed by Western blotting. The sample 
protein concentrations were determined by using a Bradford Assay (BioRad). 25 µg of 
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protein was loaded onto a 12% SOS polyacrylamide denaturing gels (PAGE) and proteins 
were separated and then transferred onto a PVOF membrane (Bio Rad, Mississauga, ON) 
at 4°C overnight. Blots were stained with amido black to determine protein transfer 
efficiency. Membranes were blocked for 2 hrs in 10% low fat milk. Blots were then 
washed with TBST (Tris-Buffered Saline with 0.5% Tween 20, TBST) for 4X10 min 
intervals and membranes were subsequently incubated with specific primary antibodies 
(Abs) at 4°C overnight. Following the primary incubation the membranes were washed 
with TBST for 4X10 min intervals. Next, membranes were incubated with specific 
secondary Abs (in 5% low fat milk) for 1 hr and then washed again in washed with TBST 
for 4X10 min intervals. Proteins of interest were then visualized by ECL 
Chemiluminescent HRP Substrate (Millipore) using the Kodak In vivo FX Pro lmager to 
detect the chemiluminescent signal which was quantified using Carestream imaging 
software. 
For immunoprecipitations, 250 µg of protein lysates in TENT++ were incubated 
with primary antibodies for goat polyclonal anti-AOIPORl (1:140, Santa Cruz Biotech, 
Santa Cruz, CA) or rabbit polyclonal anti-p27Kipl (1:140, Santa Cruz Biotech) at 4°C for 1 
hr. Then the antigen/Ab complexes were precipitated with IP/WB Optima B goat IP 
matrix (Santa Cruz Biotech) for AipoRl or rabbit IP matrix (Santa Cruz Biotech) for 
p27KIPl at 4°C overnight. The immunoprecipitated proteins were washed three times 
with TENT buffer, separated on a 12% SOS PAGE gel, and processed by Western blotting. 
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Antibodies for Western Blotting and lmmunoprecipitation. Proteins of interest 
were studied by Western blotting with primary Abs for mouse monoclonal anti-p27Kipl 
{1:3000, BD Biosciences), rabbit polyclonal anti-T198p27KIPl {1:2000, R&D Systems, 
Minneapolis, MN), rabbit polyclonal anti-p-Akt {1:500, Cell Signaling), rabbit polyclonal 
anti-Akt {1:3000, Cell Signaling), rabbit polyclonal anti-p-AMPK1172 {1:1000, Cell 
Signaling), rabbit polyclonal anti-AMPK {1:2000, Cell Signaling), goat polyclonal anti-
ADIPORl {1:2000, Santa Cruz Biotech) and mouse monoclonal anti-P-actin (1:50000, 
Abeam, Cambridge, MA) for 24 hrs at 4°C. Secondary Abs {1:5000, rabbit, mouse or goat, 
Promega, Madison, WI) or P-actin (1:20000, mouse, Promega), were incubated with the 
membrane at room temperature in 5% low fat milk for 1 hr. All protein levels have been 
corrected with P-actin, to account for any errors due to uneven loading. 
ADIPORl was immunoprecipitated to determine the amount of 14-3-3 bound. In 
this assay, 14-3-3 was detected using primary Ab monoclonal anti-pan 14-3-3 {1:1000, 
Santa Cruz Biotech) and ADIPOR1 immunoprecipitated using goat polyclonal anti-
ADIPORl (1:2000, Santa Cruz Biotech). The amount of 14-3-3 bound p27K1P1 was also 
assessed using primary Ab mouse monoclonal anti-pan 14-3-3 (1:1000 Santa Cruz 
Biotech) and p27KIPl levels were measured using mouse monoclonal anti-p27KIPl 
{1:30000, Santa Cruz Biotech). 
ADIPORl transfection was assessed by using a rabbit polyclonal myc tag {1:1000, 
Cell Signaling) and goat polyclonal anti-AdipoRl {1:2000, Santa Cruz Biotech). 
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ADIPORl cDNA amplification. Transformed DH5a E.coli bacterial cells containing 
ADIPOR1 plasmid vectors (OriGene, Rockville, MD) were obtained in glycerol stock. 
Plasmid vectors were driven by a CMV promoter with an N-terminal myc-DDk flag tag. 
Transformed cells containing ADIPOR1 were streaked on LB bacterial plates 
supplemented with 25 µg/ml kanamycin (KAN), as per manufacturer recommendations. 
Streaked LB/KAN plates were stored at 37°C overnight. Colonies were selected and 
added to 500 ml LB/KAN liquid cultures and shaken at 37°C overnight. Liquid LB/KAN 
cultures were centrifuged for 15 min at 4°C and bacterial cells resuspended in 20 ml STE 
(0.1 M NaCl, 10 mM Tris-HCI pH 8.0, 1 mM ethylenediaminetrtraacetic acid (EDTA) pH 
8.0). Plasma DNA was then purified by centrifugation through a cesium chloride gradient 
overnight at 100,000 ref. DNA was quantified using UV spectrophotometry. 
ADIPORl transfection and production of stable MCFl cell lines. Following 
isolation and purification, ADIPOR1 cDNA (5 µg) was transiently transfected into MCF7 
cells using ExGen 500 in-vitro transfection reagent (Fermentas, Burlington, ON). As per 
manufacturer's guidelines, 10.9 µI of ADIPOR1 cDNA was diluted in 589 µ1150 mM NaCl. 
The 16.45 µI of ExGen 500 was added to diluted cDNA and immediately vortexed for 10 
sec. The mixture was then incubated at room temperature for 10 min and 600 µI was 
added to three 10 cm plates of proliferating MCF7 cells. Plates were then incubated at 
37°C for 24 hrs upon which they were treated with the selection antibiotic G418 sulfate 
(400 µg/ml, Multicell), as transfected plasmids carried a G418 resistance gene. The 
concentration of G418 was determined by a killing curve with non-transfected MCF7 
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cells. A transfection using p27-YFP was also performed on separate MCF7 cells, in order 
to determine transfection efficiency. This was achieved' by adding 6.6 µI of p27-yFP 
cDNA, diluted in 593 µI of 150 nM NaCl and 16.45 µI of ExGen 500 to MCF7 cells. Over 
the period of 4-10 days, MCF7 colonies remaining after G418 selection were picked 
using a microscope and a 200 µI pipette tip. Colonies were then immediately transferred 
to a 24 well plate in AMEM. After 24 hrs the 24 well plates were subjected to 
continuation of G418 selection at 200 µg/ml to allow growth but maintain selection 
pressure. As viable colonies grew, they were subsequently trypsanized and reseeded on 
a 6 well plate and later to 10 cm plates. Once confluence reached ==70% on a 10 cm 
plate, transfected ADIPORl MCF7 cells were tested for myc tag expression and ADIPORl 
expression. From this, two viable stable ADIPORl transfected MCF7 cell lines were 
selected. 
lean and Obese Animal Models. All animal experiments were approved by the 
York University Animal Care Committee in accordance with the Canadian Council for 
Animal Care guidelines. Five (age 10 weeks) male Sprague-Dawley rats and eight (age 3 
weeks) male Sprague-Dawley rats were purchased from Charles River Laboratories 
(Montreal, QC, Canada). Only male rats were selected for this experiment because 
female rats have differences in reproductive hormones (estrogen) throughout their 
ovulatory cycle that can affect MCF7 cell growth (Lee et al., 2005). All animals had a 7 
day habituation period to a 12 hr light-dark cycle (lights on at 08:00 hours and lights off 
at 20:00 hours) in a temperature (22-23°C) and humidity (50-60%) controlled room. The 
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5 rats received at 10 weeks age were given a normal chow diet (ad libitum) for the 7 day 
habituation period (housed in groups of 2) after which they were sacrificed (mean body 
weight 363.36 g ±4.357 SEM), while the 8 rats received at 3 weeks age were fed a high 
fat diet (60% HFD) for 7 weeks (housed in groups of 2), after which they were sacrificed 
(mean body weight 588.84 g ±12.36 SEM). The lean animal group is considered the 
chow-diet (CD) control animal group. Upon time of sacrifice, aU animals were 11 weeks 
old. The 60% HFD was comprised of 60% fat, 21% carbohydrate, 18% protein and 5.1 
calories/g ad libitum (Harlan Laboratories, Madison, WI). The composition of the fat in 
the HFD was as follows: saturated: 37%; monounsaturated: 47%; polyunsaturated: 16%. 
The normal chow diet was comprised of 14% fat, 54% carbohydrate, 32% protein and 
3.02 calories/g, ad libitum. Food intake and body weight were measured every three 
days. 
Adipose Tissue Collection and Conditioned Media. Visceral (epididymal) adipose 
tissue was harvested from both CD and HFD Sprague-Dawley rats at 11 weeks old. The 
epididymal fat was then minced with scissors and cultured in 10 cm plates with Medium 
199 (Sigma-Aldrich, Oakville, Ontario) and supplemented with 2.5 nM dexamethasone 
(Sigma-Aldrich, Oakville, Ontario), 200 pM insulin (Humalog, Lilly, Toronto, Ontario) and 
1% antibiotic/antimycotic (Wisent, ST-BRUNO, Quebec) for 24 hours in an incubator at 
37°C with 5% C02• After 24 hrs, the media was switched to AMEM (Multicell) and again 
left for 24 hrs at 37°C with 5% C02, after which this new conditioned media was then 
strained of adipose tissue and stored at -84°C. All conditioned media was created by 
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Yaniv Shpilberg, but all subsequent MCF7 experiments using the conditioned media 
were done myself. 
Normal MCF7 cells and the two ADIPORl transfected MCF7 cell lines were seeded in a 6 
well plate with AMEM and left to seed for 24 hrs. The wells were then washed with 
warm PBS and conditioned media from either lean or obese animals was added for 24 
hrs. Unconditioned media plates were also used as controls. Both conditioned and 
unconditioned media plates were untreated or incubated with 18 nM of ADIPO or 300 
nM of LEP for a 24 hrs. 
Statistical Analyses. All values are expressed as means ± SEM of four to eight 
separate experiments and statistical analysis was performed using a one-way ANOVA 
with Tukeys Multiple comparisons test used when significance found. A two-way ANOVA 
with Bonferroni post-test comparisons used when significance found was used for both 
CM and FBS co-culture experiments. Statistical analyses of treatments where pS0.05 
were considered to be significantly different. 
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6. Results 
6.1 AD/PO affects pAMPK, pAktr308, p27 and ADIPOR1 in MCF7 breast cancer cells 
ADIPO has been shown in previous studies to be decreased in obese breast cancer 
patients leading to a poorer prognosis96 so we wanted to look at increasing 
concentrations of ADIPO to evaluate the effects on key cell signaling pathways (pAMPK 
and pAkt1308), their downstream cell cycle regulator targets (p27) as well as ADIPORl. 
AMPK was found to be activated via phosphorylation at residue 172 in a dose-
dependent manner with ADIPO treatment. There was a significant increase seen with an 
ADIPO concentration of both 9 nM and 24 nM displaying a 2.5-fold increase in pAMPK 
(Figure 9 A,B). The opposite effects were observed for pAktr3oa, with a negative dose-
dependent effect evident with ADIPO treatment. ADIPO caused significant decreases in 
pAktnoa by 40% at 12 nM and 60% at 24 nM (Figure 9 A,C). AMPK and Akt total protein 
content does not change with increasing concentrations of ADIPO (Figure 9 A). ADIPO 
also caused a 1.6-fold increase in p27 (Figure 9 A,D), which was mirrored by a 1.5-fold 
increase in p27 phosphorylated at T198 by AMPK (Figure 9 A,E). Both total and T198 p27 
attain significance with 12 nM ADIPO treatment, and this persists as ADIPO 
concentrations increase to 24 nM. ADIPO also caused a significant increase in ADIPORl 
(Figure 9 A,F). As little as 9 nM ADIPO elicited a 1.7-fold increase in adipoRl protein and 
continued to increase up to 2.0-fold above untreated cells with 12 nM. These 
experiments were also used to determine the optimum concentration of ADIPO to be 
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used for future studies. A concentration of 9 nM and a mid-point between 12-24 nM (18 
nM) was used for all other experiments. 
6.2 LEP affects pAMPK, pAktn°8, p27 and ADIPOR1 in MCF7 cells 
LEP has been shown to be increased in obese breast cancer patients96• We determined 
the effects of increasing LEP concentrations on activating AMPK and Akt and determined 
the downstream ramifications on p27 and ADIPORl. LEP caused a dose-dependent 
decrease in pAMPK becoming significant at 200 nM with a 50% reduction (Figure 10 
A,B). In contrast LEP induced the opposite effects on pAktnos with increases of 2.2- and 
2.6-fold at 150 nM and 200 nM, respectively (Figure 10 A,C). These results were not due 
to an increased total protein levels as neither changed with LEP treatment (Figure 10 A). 
p27 was found to be significantly lower at only 25 nM LEP by 30% and p27 levels 
remained low as LEP concentrations increased (Figure 10 A,D). The largest reduction in 
p27 was 35% at 200 nM LEP. Virtually identical results were observed for T198p27. As 
little as 25 nM LEP caused a significant 30% decrease in protein levels, which remained 
this same level with increasing concentrations of LEP {Figure 10 A,E). LEP appeared to 
decrease the protein level of ADIPORl (p=O. 70) with increasing concentrations of LEP 
reaching an average of 73% of the level in untreated cells (Figure 10 A,F). From these 
experiments it was determined that the concentrations of 150 nM and 300 nM wm be 
used in future experiments. 
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6.3 AD/PO antagonizes the effects of LEP on pAMPK, pAktr308, p27 and ADIPORl protein 
levels 
Next we wanted to co-incubate MCF7 cells with ADIPO and LEP to observe any 
antagonism between these two adipokines on AMPK and Akt signaling, in addition to 
any effects on p27, T198p27 and ADIPORl protein levels. As shown in figure 9, ADIPO 
significantly increased pAMPK, p27, T198p27 and adipoRl protein while decreasing 
pAkt1308. In contrast, LEP significantly increased pAktn°8, while decreasing pAMPK, p27, 
T198p27. 
First we looked at pAMPK and again found at a LEP concentration of 300 nM 
there was a significant 30% decrease in protein while at ADIPO concentrations of 9 and 
18 nM there was a 1.4-fold increase in pAMPK. These alterations amount to a 1.7-fold 
higher pAMPK in ADIPO treated cells above those treated with LEP {Figure 11 A,B). With 
co-treatment ADIPO was able to counteract the inhibitory effects of LEP on pAMPK, 
even at concentrations as high as 300 nM LEP. Even in the presence of up to 300 nM 
LEP, pAMPK levels were not significantly different from cells treated with ADIPO alone, 
while they were significantly higher than cells treated with 300 nM alone. In response to 
150 nM and 300 nM LEP pAktr308 levels increased by 1.6 and 1.7-fold, respectively 
(Figure 11 A,C). ADIPO caused a significant 30% decrease in pAktT308 at 18 nM as 
previously shown while with co-treatment, ADIPO cause pAktnos protein levels to not be 
significantly different then untreated. Thus, there was a 2.0-fold difference between 
pAktT308 levels in ADIPO and LEP treated cells. LEP increased pAktr308 in co-treatment 
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experiments but was unable to restore pAktr308 to levels similar to cells treated with LEP 
alone, even with the addition of 300 nM LEP. pLKBl was measured to see if the 
upstream activator of AMPK may be changing with ADIPO and LEP co-treatment. LEP 
had no effect on pLKBl protein levels while ADIPO did cause a 1.4-fold increase (Figure 
11 A,D). With co-treatment LEP attenuated the increase in pLKBl proteins level such 
that they were not different from untreated and LEP treated cells. ADIPO also caused a 
1.40-fold increase in p27 protein levels compared to untreated cells and was able to 
resist LEP-dependent reductions in p27, even at a maximum LEP concentration of 300 
nM (Figure 11 A,E). These effects on total p27 were paralleled by changes in T198p27, as 
expected, with a 1. 75-fold difference in T198p27 between ADIPO and LEP treatments. 
When co-treated with ADIPO and LEP, ADIPO was able to maintain elevated T198p27 
protein levels in the presence of both 150 nM and 300 nM LEP. Lastly, we measured 
ADIPORl protein levels and demonstrated that ADIPO caused ADIPORl to increase to 
levels that were 2.35-fold higher than those in LEP treated cells (450 nM) (Figure 11 
A,G). With co-treatment, LEP caused a dose-dependent decrease in ADIPORl in the 
presence of 9 or 18 nM ADIPO. Unlike the other proteins measured, LEP was able to 
completely antagonize ADIPO-dependent increases in ADIPORl protein levels. 
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Experiments using even higher LEP concentrations (450 nM) revealed that at this high 
concentration LEP was able to completely overcome ADIPO effects on ADIPORl protein 
levels at both 9 and 18 nM ADIPO concentrations. 
6.4 Akt Inhibition mimics the effects of AD/PO in MCF7 breast cancer cells 
MCF7 cells were treated with an Akt inhibitor to see whether Akt inhibition can mimic 
the effects of AMPK activation using ADIPO. Akt inhibition caused effects similar to 
ADIPO on pAMPK, pAktT3°8, p27 and ADIPORl. pAMPK displayed dose-dependent 
increases reaching statistical significance (1.60-fold) at an Akt inhibitor concentration of 
10 nM (Figure 12 A,B). As expected, the Akt inhibitor caused dose-dependent decreases 
in pAktT308 reaching levels that were 70% lower than those in untreated cells at 10 nM 
(Figure 12 A,C). Akt inhibition caused a 1.8-fold increase in p27 protein levels at 10 nM 
treatment (Figure 12 A,D), while T198p27 demonstrated similar effects with a 1.5-fold 
increase at 10 nM. ADIPORl also demonstrated increased protein levels following 
treatment with the Akt inhibitor. Treatment with only 4 nM induced a 2.10-fold increase 
in adipoRl (Figure 12 A,F) and protein levels continued to rise reaching a maximum of 
2.55-fold at 10 nM. These experiments illustrate the powerful effect that Akt inhibition 
has on ADIPORl protein levels in a manner similar to ADIPO treatment. 
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6.5 Akt inhibition and AD/PO elicit additive effects on pAktr308 and p27 in MCFl cells 
Since ADIPO and Akt inhibition lead to similar increases in pAMPK, p27 and T198p27, we 
wanted to observe whether co-treatment would lead to additive or synergistic effects 
on these protein levels. ADIPO (18 nM) increased pAMPK 1.75-fold while co-treatment 
of 18 nM ADIPO and 2 nM Akt inhibitor resulted in no further increases above ADIPO 
alone (Figure 13 A,B). Next we looked at the co-treatment on pAktT3°8• ADIPO decreased 
pAktT308 30% and the addition of an Akt inhibitor resulted in a further decrease to 50% 
of the levels in untreated cells (Figure 13 A,C). As previously shown, ADIPO increased 
p27 1.5-fold, with an even greater increase evident with co-treatment, reaching levels 
that were 2.0-fold above those in untreated cells (Figure 13 A,D). ADIPO also caused a 
1.4-fold increase in T198p27 but no further increase was observed with co-treatment 
(Figure 13 A,E). Lastly, ADIPO increased ADIPORl protein by 1.6-fold but the addition of 
an Akt inhibitor showed no further increases in ADIPORl protein levels (Figure 13 A,F). 
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6.6 ADIPOR1 binds to 14-3-3 and Akt 
Since ADIPORl contains a 14-3-3 and Akt consensus binding site at T68 I evaluated 
whether 14-3-3 and Akt did indeed interact with ADIPORl by immunoprecipitating 
ADIPORl. The justification for this experiment is that LEP causes an increase in pAkt 
which may decrease the stability of ADIPORl. Lysates from arrested MCF7 cells showed 
a 1.7-fold increased interaction between 14-3-3 and ADIPORl compared to untreated 
cells (Figure 14 A,B) This binding was higher than that observed for all other conditions 
except for the 18 nM ADIPO treatment. ADIPORl/14-3-3 binding was evident in all other 
conditions but there was no significant difference in binding between conditions. In 
addition to a 14-3-3 binding site, there is also a potential Akt phosphorylation site (T68) 
on ADIPORl. Akt was found bound to 14-3-3 in all conditions and may help confirm the 
possible interaction Akt has with ADIPORl (Figure 14 A). 
6.7 14-3-3 binds to p27 
Given that 14-3-3 interactions have been shown to affect protein stability, we evaluated 
the possible interaction of 14-3-3 with p27 during conditions where p27 proteins levels 
were changing. Only the 300 nM LEP and 1 mM Compound C treatments were found to 
be significantly different from untreated cells despite variability in the mean p27 values 
amongst groups. LEP was found to cause a 55% decrease while Compound C caused a 
60% reduction in 14-3-3 binding to p27 (Figure 15 A,B). ADIPO treatment (18 nM), 
caused an approximate 2-fold higher amount of 14-3-3 bound to p27 than LEP and 
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Compound C and a 1.3-fold higher 14-3-3/p27 interaction observed with Akt inhibitor 
treatment (Figure 15 A,B). All other treatments were found to not display a significantly 
different amount of 14-3-3 binding to p27 compared to other treatments. 
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Figure 14: AdipoRl immunoprecipitation for bound 14-3-3 protein levels. Effects of 14-3-3 
bound AdipoRl with treatments of Arrest, ADIPO 18 nM, LEP 300 nM, Akt Inhibitor 10 nM 
and Estrogen 10 nM. IGG is also shown. Blots standardized to AdipoRl to correct for loading. 
Any letters which differ in treatment represent a significant difference (p<0.05). n=8/group 
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Figure 15: p27 immunoprecipitation for bound 14-3-3 protein levels. Effects of 14-3-3 bound 
p27 with treatments of Arrest, ADIPO 18 nM, LEP 300 nM, Akt Inhibitor 10 nM AICAR 1 mM 
and Compound C 1 mM. Blots standardized to p27 to correct for loading. Any letters which 
differ in treatment represent a significant difference (p<0.05). n=8/group 
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6.8 Selection of a stable ADIPOR1 overexpressinq MCF7 cell line 
To evaluate the role of ADIPORl in MCF7 cell cycle regulation, we created a cell line 
stably transfected with an adipoRl expression plasmid. Seventeen individual stable 
transfected cell lines exhibiting G418 resistance were tested for Myc-tag protein 
levels/expression. Of the 3 cell lines which all had the highest expression of the Myc-tag, 
p31-3-2 was found to display the highest Myc-tag expression. Two other clones, p31-4-
2-2 and p33-1-1 also showed high levels of Myc-tag expression (Figure 16 A,B). In 
addition, we wanted confirm increased plasmid expression by looking at the amount of 
ADIPORl protein. p31-3-2 was found to display a 1.3-fold higher ADIPORl compared to 
wild-type MCF7 cells, while p31-4-2-2 showed a 1.6-fold increase in ADIPORl protein 
levels (Figure 16 A,C). Although clone p33-1-9 showed the greatest increase in ADIPORl 
protein levels, it showed one of the lowest Myc-tag expressions and therefore we didn't 
use this clone for future experiments. p31-4-2-2 had a larger increase in adipoRl protein 
levels than p31-l-l. Therefore, p31-4-2-2 and p31-3-2 were chosen as they showed the 
highest levels of both the Myc-tag and ADIPORl protein while providing a difference in 
ADIPORl protein levels to observe the result of different ADIPORl activation. 
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Figure 16: AdipoRl transfection assessment. Successfully plated cell lines who survived G418 
selection were tested for (B) Myc Tag and (C) AdipoRl. Two transfected cell lines (red) were 
then chosen for further experiments due to both increased Tag and adipoRl protein levels. 
Blots standardized to ~-actin to correct for loading. 
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6.9 AdipoRl overexpression can abolish the LEP-dependent effects in breast cancer cells 
The stable cell lines created above were used in ADIPO/LEP co-treatment experiments. 
pAMPK levels were over 2-fold higher in ADIPO than in LEP treated cells (Figure 17 A,B). 
With co-treatment pAMPK was lower than with ADIPO treatment but higher than LEP 
treatment alone. In the p31-4-2-2 cell line, no difference between pAMPK levels in 
untreated, ADIPO and LEP were evident despite overall pAMPK levels being higher in 
this cell line, as expected (Figure 17 A,B). Only the co-treatment was found to be 
elevated, with a 1.8-fold increase compared to untreated, but no difference was 
observed when compared to ADIPO and LEP treatments alone. In the p31-3-2 
transfected cell line, ADIPO caused a 1.65-fold increase in pAMPK. Both the LEP and co-
treatment demonstrated pAMPK levels similar to ADIPO but they were not significantly 
different than those in untreated cells due to larger error (Figure 17 A,B). Next we 
evaluated pAktT3°8• pAktr308 protein in ADIPO treated cells was 2.5-fold lower than in LEP 
treated cells (Figure 17 A,C). Co-treatment increased pAktT308 protein levels higher than 
those in cells treated with ADIPO alone. Interestingly in both adipoRl overexpressing 
cell lines there is no change in pAktnos levels between all treatment groups compared to 
the untreated condition (Figure 17 A,C). Changes in pAMPK and pAktT308 protein levels 
were not due to increases in total protein levels (Figure 17 A). p27 levels were 2.5-fold 
higher in ADIPO treated cells compared to LEP treated cells (Figure 17 A,D). Co-
treatment caused p27 to stay at the same level as untreated cells and a level that was 
significantly lower than ADIPO treatment alone. The p27 response in ADIPORl 
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Figure 17: ADIPO & LEP 24 hr co-treatment in wild type (black), p31-4-2-2 (stripped) and p31-
3-2 (grey) with effects on (B) pAMPK, (C) pAkt, (D) p27 and (E) T198p27 and (F) AdipoRl 
protein levels. Blots standardized to ~-actin to correct for loading. All 3 cell lines compared to 
same cell line untreated condition. Letters which are different represent a significant 
difference (p<0.05). n=3/group 
overexpressing cells was similar to pAktn°8• p27 levels in all conditions were not 
significantly different than in untreated conditions. When evaluating T198p27 protein 
levels, ADIPO caused an approximate 2.5-fold increase compared to LEP treated cells 
and co-treatment brought T198p27 levels up to levels similar to those seen in ADIPO 
treated cells (Figure 17 A,E). T198p27 protein levels followed the same pattern as 
pAkt nos and p27 with the two ADIPORl stable cell lines. All treatment conditions were 
not significantly different than untreated, including the LEP treatments. Lastly we again 
evaluated ADIPORl protein levels that ADIPO caused an almost 2-fold increase in 
ADIPORl expression compared to LEP treated cells (Figure 17 A,F). Co-treatment 
reduced ADIPORl levels to those seen with LEP treatment alone. There were no 
significant changes in either stably transfected cell lines with ADIPO, LEP or co-
treatment. From these results we concluded that both transfected cell lines appear to 
counteract the effects of LEP and will both be used as we moved forward to the animal 
experiments. 
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6.10 HFD fed animals had significantly more epididymal fat than the normal CD fed 
animals 
HFD feed animals showed rapid gains in mass for the entire protocol and were 1. 7-fold 
heavier than their age matched CD fed animals at sacrifice {Figure 18 A). Consistent with 
this increased body weight was a significant 3.2-fold increase in epididymal fat pad mass 
(per 100 grams of body weight). These results clearly show that the HFD was effective in 
increasing body mass and visceral adiposity and represents an accurate obesity model. 
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Figure 18: (A) Comparison of body mass between CD and HFD rats at time of sacrifice. (B) 
Comparison of the epididymal fat extracted per lOOg body weight between CD and HFD rats 
Letters which are different represent a significant difference (p<0.05). CD n=5, HFD n=8 
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6.11 Conditioned media from adipocytes from HFD and CD fed animals induced effects 
on pAMPK, pAktr308, p27 and ADIPOR1 proteins in wild type MCFl cells 
Our next experiments were designed to see if our ADIPO/LEP antagonism model 
persisted in an environment that more resembled an in-vivo condition where a wide 
variety of adipokines are present. To do this, we created conditioned media (CM) by 
culturing crude adipocyte preparations from CD and HFD fed rats and incubating 
proliferating MCF7 cells with either AMEM (containing 10% FBS alone) or CM for 24 hrs. 
pAMPK protein levels were higher in cells with CM from CD animals compared to cells in 
CM from HFD adipocytes (Figure 19 A,B). The effects of ADIPO and LEP in FBS and CD-
CM treated cells were similar, however these treatment effects were abolished in HFD-
CM treated cells. When comparing the effects of CM, HFD caused a reduction in pAMPK 
in UT, ADIPO and LEP treated cells compared to cells incubated with CD-CM. Most 
notable was a 75% decrease in pAMPK with ADIPO in HFD-CM compared to the CD-CM. 
Similarly, pAktnos levels were affected by CM (Figure 19 A,C). CD-CM and HFD-CM 
induced different effects on pAktr308 then as seen in pAMPK protein levels. Cells 
incubated with AMEM FBS media showed similar results from previous studies with 
ADIPO and LEP treatments (Figure 9, 10). When comparing CD and HFD media 
conditions, we found that pAktr308 levels in all three treatments were significantly 
increased compared to the same treatments with CD-CM. In response to ADIPO 
treatment we see that the HFD-CM increased pAktnos 1.60-fold above CD-CM treated 
cells. For both p27 and T198p27 we observed the same differences between both 
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Figure 19: ADIPO and LEP 24 hr treatment using conditioned media from FBS (open1), CD 
(black) or HFD (grey) in wild type cells with effects on (B) pAMPK, (C) pAkt, (D) p27, (E) 
T198p27 and (F) AdipoRl protein levels. Blots standardized to ~-actin to correct for loa~ding. 
Letters which are different represent a significant difference in conditioned media, numbers 
significant difference in treatment and symbols represent an interaction (p<0.05). A $ 
indicates a significant difference in a treatment between CD-CM and HFD-CM (p<0.05). n=ll 
(FBS), n=5 (CD), n=6 (HFD)/group 
conditions and treatments, with CD-CM increasing p27 and T198p27 above HFD-CM. In 
CD-CM there was no effect of ADIPO or LEP on p27 or T198p27. HFD-CM also abol1ished 
the effects of ADIPO and LEP on these two proteins. HFD-CM altered the ADIPO effects 
on p27 and T198p27 protein levels with measured reductions of 85% and 75% in p27 
and T198p27 protein levels, respectively. Lastly, CD-CM and HFD-CM showed the same 
effect on ADIPORl as p27 (Figure 19 A,F). ADIPOR1 protein levels were higher with CD-
CM treatment compared to HFD-CM exposure. The effects of ADIPO and LEP on 
ADIPORl in FBS treated cells were abolished in both CD-CM and HFD-CM conditions. 
There is a significant 2.25-fold increase in adipoRl protein with ADIPO treatment in CD-
CM compared to HFD-CM experiments 
From these results, we see that the CD-CM increases pAMPK, p27, T198p27 and 
AdipoRl while decreasing pAktr308• Each of these alterations likely lead to cell cycle exit 
and would be indicative of an inhibitory tumor growth microenvironment. The opposite 
is true of HFD-CM suggesting that obese adipocytes promote breast cancer 
proliferation. 
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6.12 ADIPOR1 overexpression ameliorates the effects on protein levels caused by HFD 
Following our previous results we wanted to determine what affect ADIPORl 
overexpression would have on HFD-CM effects. Our first experiments utilized the p31-3-
2-2 cell line that had the highest ADIPORl expression. First we looked at pAMPK and 
found similar results to those seen in non-overexpressing cells (Figure 20 A,B vs. Figure 
19, A,B). However, the pAMPK levels in all ADIPORl overexpressing cells were higher 
than in non-transfected cells. Most importantly, pAMPK in HFD-CM cells was higher 
than FBS treated non-transfected cells suggesting that increasing ADIPORl can lessen or 
even completely abolish HFD-dependent decreases in pAMPK. This effect of ADIPORl 
over-expression was evident for other proteins. In the p31-4-2-2 line there was no 
enhancement of pAktnos with HFD-CM compared to FBS and CD-CM cells (Figure 20 
A,C). Similarly, all of the decreases in p27, T1987p27 and ADIPORl induced by HFD-CM 
in wild-type MCF7 cells (Figure 19 A,D-F) were no longer evident when ADIPORl was 
over expressed (Figure 20 A, D-F). These results show that increasing ADIPORl 
expression can alter the tumor growth promoting environment created by HFD/obesity. 
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Figure 20: ADIPO and LEP 24 hr treatment using conditioned media from either FBS (open), 
CD (black) or HFD (grey) in p31-4-2-2 cells with effects on (B) pAMPK, (C) pAkt, (D) p27, (E) 
T198p27 and (F) AdipoRl protein levels. Blots standardized to ~-actin to correct for lo~ding. 
Letters which are different represent a significant difference in conditioned media, numbers 
significant difference in treatment and symbols represent an interaction (p<0.05). A $ 
indicates a significant difference in a treatment between CD and HFD (p<0.05). n=ll (FBS), 
n=5 (CD), n=6 (HFD)/per group 
The final experiments utilized the stably transfected cell line p31-3-2 which had the 
highest myc-tag expression levels. Overall, we observed similar results to those seen 
using p31-4-2-2 cell line (Figure 20). For pAMPK, HFD-CM reduced protein levels 
compared to CD-CM (Figure 21 A,B), but even in the presence of HFD-CM pAMPK levels 
were higher in p31-3-2 cells than in FBS treated non-transfected MCF7 cells (Figure 19 
A,B). HFD-CM did not increase pAktT308 above the levels seen in FBS and CD-CM 
experiments (Figure 21 A,C). HFD-CM decreased p27 levels compared to CD-CM 
treatment, but the absolute levels of p27 were higher in p31-3-2 cells treated with HFD-
CM that in non-transfected MCF7 cells grown in FBS (Figure 19 A,D). T198p27 and 
ADIPORl protein levels were unaffected by HFD-CM (Figure 21 A,E,F). These results 
agree with those from our p31-3-2-2 line which had the highest ADIPORl protein levels 
(Figure 20). Taken together, these results suggest that activation of ADIPO signaling by 
increasing ADIPORl protein levels can counteract the growth promoting effects of 
adipocytes from obese animals. 
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Figure 21: ADIPO and LEP 24 hr treatment using conditioned media from either FBS (open), 
CD (black) or HFD (grey) in p31-3-2 cells with effects on (B) pAMPK, (C) pAkt, (D) p27, (E) 
T198p27 and (F) AdipoRl protein levels. Blots standardized to ~-actin to correct for loading. 
Letters which are different represent a significant difference in conditioned media, numbers 
significant difference in treatment and symbols represent an interaction (p<0.05). A $ 
indicates a significant difference in a treatment between CD and HFD (p<0.05). n=ll (FBS), 
n=5 (CD), n=6 (HFD)/group 
73 
7. Discussion 
Breast cancer continues to be a growing concern in our society and due to the 
increase in the number of cases 1, partly due to better technology for early detection 
which also translates to an increased number of deaths. Despite the increase in the 
absolute number of deaths, early detection results in the discovery of lower grade 
tumors which respond better to therapies and decrease the overall percent mortality 
rate 1• Breast cancer therapies employed in the clinic have remained relatively 
unchanged over the last 20 years. To address this, more emphasis has been placed on 
understanding the underlying molecular mechanisms which lead to cancer development 
and progression. 
Obesity like breast cancer has been on the rise over the last 20 years. As 
previously stated, more than 1.4 billion people worldwide are considered obese and the 
numbers are continuing to increase 68• This increase in obesity is becoming a growing 
concern as there has been a statistical association between increasing adiposity and an 
increased risk of cancer for over 40 years 75 • Thus, it is likely that the increase in breast 
cancer incidence may be due, in part to increases in obesity. 
Adipose tissue has been traditionally considered to be an inert storage depot for 
excess energy but now has been shown to be a highly active endocrine tissue producing 
potential growth factors termed adipokines 82' 83 • The adipokines ADIPO and LEP have 
come to the forefront of research as they have been shown to be the most abundant 
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adipocytokines produced by adipoctyes and have been shown to affect the growth 
status of cells, including breast cancer cells 84• Studies have shown that in breast cancer 
patients, the serum ADIPO:LEP ratio is significantly decreased which has been shown to 
occur in obese individuals 90' 93' 94• Understanding the ramifications of this shift in the 
ratio between ADIPO and LEP is one of the key mechanisms studied in my thesis as well 
understanding how these two adipokines affect certain key cell cycle regulatory 
proteins. 
Previous research by Dieudonne et al. (2006) showed how ADIPO causes a dose-
dependent increase in pAMPK which has also been previously shown in our lab 129• My 
findings again showed this with ADIPO causing a significant increase in pAMPK and a 
significant decrease in pAkt (Figure 9 A,B,C). LEP induced the opposite effect as shown in 
figure 9, producing a significant decrease in pAMPK 113 and a novel significant increase in 
pAkt (Figure 9 & 10 A,B,C). I believe that it is this interaction between ADIPO and LEP 
through both AMPK and Akt that may be causing the effects on cell proliferation status. 
With ADIPO and LEP co-treatment, I show that ADIPO is able to overcome both the 
inhibitory effects that LEP has on pAMPK and the increase observed in pAkt (Figure 11 
A,B,C). It is this antagonism between ADIPO and LEP. that I believe is key to all the 
downstream cell cycle effects, specifically with respect to the cell cycle regulator p27. It 
appears that it is the relative concentration, or ratio between the two adipokines, and 
not the absolute concentration that is of importance. If we can alter the ratio of 
ADIPO:LEP, which can be achieved naturally through weight loss by means of exerdse or 
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energy restriction 139, it may create a negative growth environment for breast cancer 
cells. This would agree with a previous study that showed ADIPO activated AMPK can 
stimulate the dephosphorylation of Akt 134, which is consistent with my findings. It may 
be possible that once the ADIPO:LEP ratio reaches a high enough level, we see enough 
ADIPO to cause AMPK to lead to the dephosphorylation of Akt by PP2A. This mechanism 
only explains an increase in AMPK leads to a decrease in Akt but does not address the 
novel results I show of how increasing Akt plays a role in decreasing AMPK. It may be 
possible that AMPK and Akt also have direct antagonism of one another or that Akt may 
also activate a different phosphatase which de-activates AMPK. 
In order to look at the downstream effects of this ADIPO:LEP antagonism, 
observed the effects on both p27 as well as T198p27, which is directly phosphorylated 
by AMPK 45• p27 is an important regulator of cell cycle progression and regulates the 
important Gl-5 phase transition 15' 19' 25' 32• Research has shown that activation of AMPK 
leads to the phosphorylation of human p27 at T198, which increases the stability of p27 
protein 45• Previous and current research in our lab has shown that ADIPO causes a 
significant 1.6-fold increase in p27 while LEP produces the opposite effect (Figure 9 A,D 
& 10 A,D). Previous studies reveal that an increase in p27 protein concentration to the 
magnitude achieved (Figure 9 A,D) corresponds with full cell cycle arrest in MCF7 cells 
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I show the same effects on T198p27 with ADIPO and LEP treatment (Figure 9 & 
10 A,D,E). Interestingly with co-treatment, as opposed to pAMPK and pAkt, where LEP 
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did have slight effects on both proteins, p27 and T198p27 showed no change from 
ADIPO treatment and co-treatment of ADIPO and LEP. LEP was unable to antagonize the 
effects of ADIPO on p27 and T198p27. 
In order to further understand how phosphorylation at T198 could lead to more 
overall p27 protein stability, we looked at the possibility of 14-3-3 interacting with and 
stabilizing p27. Previous work by Short et al. (2010), showed how activation of AMPK 
leads to the phosphorylation of p27 at the conserved sequence of the C-terminal 
threonine residue of the murine p27 (T197), similar to the human T198 binding site 140• 
Mutation of T197 to 0197 led to an increased interaction between p27 and 14-3-3 
which resulted in increased p27 protein stability. They also discovered that this 
increased stability of p27 protein was dependent on T197 phosphorylation by 
introducing a T198A mutation 140• From the use of an immunoprecipitation of p27, 
subsequently probed for 14-3-3, I found that both CC and LEP caused significant 60% 
decreases in the amount of 14-3-3 that was bound to p27 compared to arrested cells 
(Figure 15). My experiments have shown that LEP causes a significant decrease in active 
AMPK while previous research in our lab has shown the same inhibition of AMPK with 
CC treatment. If we compare the treatments back to the arrested cells we see that both 
LEP and CC treatments are significantly lower 14-3-3 binding to p27 and have a 
corresponding decrease in pAMPK and T198p27. We had expected ADIPO, AICAR and 
Akt inhibition to cause a significantly higher amount of 14-3-3 bound p27 than both LEP 
and CC as they have been shown to increase pAMPK as well as T198p27. When 
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comparing the relative differences in protein levels of both p27 and T198 (Figure 9 D,E & 
Figure 10 D,E) we see that they follow the same trend as they correlate with the amount 
of 14-3-3 bound to p27 (Figure 15). There is a doubling of pAMPK which causes <double 
the amount of T198 with ADIPO treatment compared to LEP. This corresponds wi 1th the 
amount of 14-3-3 binding to p27, with slightly more than double the amount of 14-3-3 
bound to p27 with ADIPO treatment compared to LEP treatment. This same trend was 
previously shown using ADIPO and CC in our lab when comparing pAMPK, T198 and p27 
protein differences. ADIPO caused over double the amount of T198 phosphorylation, 
leading to over double the amount of p27 /14-3-3 binding and a subsequent 2 fold 
increase in p27. These results agree with the molecular results by Short et al., (2010), 
who employed an in vivo model using transgenic mice expressing mutant forms of p27 
140
• Therefore, I believe that this pathway may be the means of which active AMPK 
causes the stabilization of p27 which agrees with the results from previous studies 
..... ,.., ~ ... 
(Figure 22) 140• This may also explain why decreasing active AMPK through CC or LEP 
decreases the amount of 14-3-3 binding and in turn decreases p27 stability. What is 
unclear with LEP treatment is whether it is the decrease in pAMPK or the increase in 
pAkt that is causing this decrease in 14-3-3 binding and p27 protein levels. Although 
mutations give insight into the potential role of phosphorylation into protein functions, 
they are not truly representative of physiological cellular function. By treating cells with 
ADIPO and LEP and showing similar results, I have given physiological relevance to this 
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AMPK dependent phosphorylation on p27 /14-3-3 interaction and defined a potential 
role in human breast cancer. 
')'pAMPK --7 1'T198 --71'14-3-3 --7')'p27 
ADIPO vs. LEP --7 1' 2-fold --7 1' 2-fold --7 1' 2.3-fold 
ADIPO vs. Comp C --7 1' >2-fold --7 1'>2-fold ~ 1'2-fold 
Figure 22: Possible relationship between increases in active AMPK, leading to 
increased phosphorylation of T198, increased binding of 14-3-3 to p27 causing 
increased stability. 
Also novel to this study was the discovery of the effects of ADIPO and LEP on 
ADIPORl protein. I show that ADIPO causes a significant increase in ADIPORl in a 
positive feedback manner while LEP appears to decrease ADIPORl trend (Figure 9 & 10 
A,F). The co-treatment displayed an important result as LEP caused a significant 
decrease in ADIPORl, even in the presence of ADIPO (Figure 11 A,F). Therefore I believe 
that it is this LEP-dependent decrease in ADIPORl that may be driving the proliferative 
effects induced by LEP in MCF7 cells. This is supported, in part through a study by Pfeiler 
et al. (2010) which showed that women with the most aggressive breast tumors had 
decreased ADIPORl protein expression 127• Furthermore, ADIPORl expression is 62% 
lower in obese women compared to lean women in visceral adipose tissue 128• I believe 
that this decrease in ADIPORl either through a decrease in pAMPK or an increase in 
pAkt could be regulating ADIPORl signaling. Thus, in an obese individual, where the 
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ratio of ADIPO:LEP is decreased, this compounding effect on decreasing ADIPORl would 
only worsen the effectiveness of ADIPO which already exists at lower levels in obese 
individuals. 
In order to determine if Akt was directly responsible for these effects on 
ADIPORl, pAMPK, p27 and T198p27, a pharmacological Akt inhibitor was utilized. I was 
able to show for the first time that Akt appears to play an important role in ADIPORl 
protein stability. As shown in figure 12, the use of an Akt inhibitor caused the same 
effects on ADIPORl as ADIPO treatment, mirroring the exact same fold protein changes. 
These results also resemble previous research done in our lab which looked at AMPK 
activation through AICAR, an AMP mimetic. Therefore, the same overall effects on 
pAMPK, pAkt, p27 and T198p27 are achieved by either activating AMPK or inactivating 
Akt. Interestingly, I showed that Akt may play a pivotal role in ADIPORl stability, as 
there is a significant dose-dependent increase in ADIPORl with Akt inhibition similar to 
that seen with ADIPO treatment. 
I wanted to determine whether given these changes in ADIPORl in response to 
AMPK activation and Akt inhibition, increasing the amount of ADIPORl would have any 
effect on p27 in MCF7 cells. In order to do so, I created numerous stably ADIPORl 
transfected cell line which showed a significant increase of ADIPORl protein compared 
to non-transfected MCF7 cells (Figure 16 A,B,C). With two of these transfected cell lines, 
I show that an increase in ADIPORl protein and resultant ADIPORl downstream 
signaling abolished all of the LEP-dependent effects on p27 (Figure 17). By increasing the 
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amount of ADIPORl present in the cells they are resistant to LEP, possibly by utilizing 
more of the existing ADIPO present in the FBS, even in the presence of high LEP 
concentrations. Also important to note is the overall protein levels in the ADIPORl 
overexpressing cells compared to the non-transfected MCF7 cells. If we look at figure 17 
A, the transfected cell lines have more pAMPK, p27, T198p27 and of course more 
adipoRl while displaying less overall pAkt then the non-transfected cells. Given that 
increasing pAMPK, p27 and T198p27 are associated with cell cycle 
inhibition/withdrawal, increasing ADIPORl protein may inhibit proliferation of breast 
cancer cells, even in an obese patient with a low ADIPO:LEP ratio. 
Akt inhibition caused a large dose-dependent increase in ADIPORl protein and I 
wanted to determine if this possible increase was caused by Akt signaling affecting the 
interaction with potential stabilizing proteins. To accomplish this, a stringent Scansite 
blast search (scansite.mit.edu) was used to identify potential protein-protein interaction 
sites with ADIPORl. It was discovered that there may be a potential Akt consensus site 
(RXRXXS/T) at T68 which shares homology with the consensus 14-3-3 binding motif 
(RSXS/TXP). It was then hypothesised that Akt may phosphorylate ADIPORl at T68 
which then affects 14-3-3 binding to the same consensus site, thereby affecting 
ADIPORl protein stability. Through the use of an immunoprecipitation of ADIPORl, I 
probed for 14-3-3 and found that in arrested MCF7 cells there is a significant 1.70-fold 
increase in 14-3-3 bound to ADIPORl then in untreated proliferating cells (Figure 14). 
Interestingly, differences in 14-3-3 bound to ADIPOR1 with LEP treatment were similar 
81 
to decreases in ADIPORl protein with LEP treatment. If Akt were directly responsible for 
14-3-3/ ADIPORl interaction, Akt inhibition should cause an increase in the amount of 
14-3-3 bound to ADIPORl. This was not evident and therefore I believe that 14-3-3 
binding to ADIPORl affects ADIPORl stability but is probably not mediated through Akt. 
Although I didn't see the results hypothesised with the use of an Akt inhibitor, I did 
show that Akt does bind to ADIPORl in all experimental conditions. One other possibility 
may be that there is also a consensus site for pyruvate dehydrogenase kinase 1 (PDKl) 
on ADIPORl (Scansite). Previous research has shown that PDKl acts as the upstream 
activator of Akt 141 and it may be that PDKl mediating 14-3-3 binding to ADIPORl. 
Therefore, Akt may still phosphorylate ADIPORl at T68 but more work needs to be done 
in order to precisely determine direct Akt effects on ADIPORl. 
Excess obesity, especially visceral adipose tissue, has been found to be 
associated with many negative health factors, including some forms of cancer 69' 73' 74• 
The decrease in ADIPO:LEP of an obese woman is one possibility that likely drives the 
proliferation of breast cancer in obese patients 84' 88' 89 • Previous research has shown 
that serum LEP and ADIPO levels are positively and negatively correlated to BMI, 
respectively 94• I wanted to determine if the proliferating effects of LEP achieved by 
increasing ADIPORl in MCF7 cells could either be increased or decreased depending on 
the adipocyte profile it was exposed to. To evaluate this, we cultured primary crude 
adipose tissue from obese HFD fed rats and generated conditioned MCF7 growth media 
(HFD-CM). We also generated CM from lean age matched normal chow diet fed animals 
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(CD-CM). This allowed us to compare the effects of increasing ADIPORl protein 
expression in the presence of a complete adipokine profile that a breast cancer would 
be exposed to. The CD-CM activated AMPK and increased p27 and T198p27 while 
inhibiting the activation of Akt, which was also the case in cells treated with ADIPO 
alone. The HFD-CM produced exactly the opposite effects. This HFD work agrees with 
previous research conducted in our lab which showed that adipocytes from ZDF rats 
induced cell cycle entry in MCF7 cells 113• Non-transfected MCF7 cells in CD-CM were 
capable of blunting LEP effects on p27 while ADIPO was able to counteract the 
reduction in p27 caused by the HFD-CM (Figure 19). The CD-CM caused an increase in 
pAMPK and a subsequent decrease in pAkt, which agrees with the idea that a lean diet 
creates a growth inhibitory tumor microenvironment possibly by increasing the 
ADIPO:LEP ratio 94• The opposite effect is observed with HFD-CM, creating a positive 
tumor growth environment promoting proliferation. Importantly, even in the presence 
of all other adipokines and factors within CD-CM and HFD-CM, the results follow the 
ADIPO:LEP pattern I have previously shown (Figure 19). Therefore I believe that it is a 
distinct possibility that ADIPO and LEP are the two main adipokines which are driving 
the results observed throughout this study, possibly through the changes in the ratio of 
pAMPK/pAkt. This is beneficial for breast cancer patients because if these are the two 
main adipokines driving the growth environment of their tumors, previous work has 
shown that weight loss can increase the ADIPO:LEP ratio 139 and increase ADIPORl 
expression in visceral and subcutaneous adipose tissue 128• Each of these factors increase 
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p27 by phosphorylation via AMPK which will ultimately lead to cell cycle arrest. In 
addition, even in an obese environment, increasing the amount of ADIPOR'l can 
minimize the reduction in p27 caused by LEP. Thus maintenance of ADIPORl signaling 
either pharmacologically or naturally via diet and exercise, can potentially inhibit breast 
cancer proliferation and improve patient prognosis. 
The changes produced in this study are stable changes which are not specific for 
a certain tumor type. Although I used MCF7 breast cancer cells, many other cancers 
including colon cancer 142, endometrial cancer 143, prostate cancer 144 and acute 
myelogenous leukaemia 145 to name a few, have been shown to be increased with a 
decrease in the ADIPO:LEP ratio. The method of controlling the ADIPO:LEP ratio and 
subsequent positive cell cycle effects would act as a blanket inhibition of tumor growth, 
possibly irrelevant of the genetic situation of the specific tumor. 
The data obtained from these experiments have provided sufficient information 
to develop a working model of the possible signalling cascade of events which occur 
from both obese and lean adipocytes in relation to cell cycle status (Figure 23). From 
previous work in our lab which supports my data, I believe that active AMPK helps 
stabilize ADIPORl. We see that ADIPORl protein is increased with ADIPO and AICAR 
treatment while CC causes a significant reduction in ADIPORl, displaying the importance 
of AMPK in regulating ADIPORl protein· levels. By increasing ADIPORl expression, a 
positive feedback loop is created, producing more active AMPK which in turn help 
stabilize p27 through 14-3-3 binding/interaction, leading to cell cycle arrest. This 
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increased AMPK also may control active pAkt levels which acts in an opposing manner to 
promote cell cycle progression subsequently via decreasing p27 and its phosphorylation. 
Akt may also play a role in further inhibiting AMPK and ADIPORl protein levels and 
stability. Therefore, an individual who is obese has a decrease in their ADIPO:LEP ratio, 
causing increases in active Akt, decreases in active AMPK and a subsequent decreases in 
p27 leading to cell cycle entry. They also now seem to have less ADIPORl, which would 
decrease the positive feedback loop produced by ADIPO to increase/stabilize ADIPORl 
protein levels. If we can activate AMPK to increase ADIPORl via AICAR, the use of ADIPO 
treatment or diet and exercise, we may be able to create a more negative growth 
microenvironment for the tumor. Fully understanding the relationship between ADIPO 
and LEP may link a physiological/molecular relationship between obesity, breast cancer 
and cell cycle regulation. 
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Figure 23: Current working model based on data collected. The ratio between 
ADIPO:LEP based on weight and adipokine profile affect downstream pathways 
AMPK and Akt. Unclear is whether AMPK is controlling Akt or vice versa. 14-3-3 
seems to play a stabilizing role with both p27 and adipoRl while Akt seems to play a 
role in destabilizing ADIPORl 
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8. Future Directions and Limitations 
This study tries to further the research into the effects of the two adipokines 
ADIPO and LEP on breast cancer development and progression. There are other possible 
means by which I can further support my data that has been collected. First, I will be 
utilizing the MCF7 cells that I have collected during the conditioned media study which 
were placed in ethanol in order to run a FACS analysis. The cells were collected at the 
same time as the treatments in both non-transfected and transfected MCF7 cells. This 
will confirm my hypothesis that the HFD media is causing more cells to enter the cell 
cycle while the CD-CM caused more cells to arrest in Gl. Also, I would want to 
determine if the transfected cells caused more cells to enter Gl with the CD-CM than 
the non-transfected MCF7 cells. Also interesting would be whether these ADIPORl 
transfected cells increased the number of cells in Gl even with the HFD-CM. This would 
only further stress the importance of ADIPORl and the environment created by the 
adipocyte. 
In the future I would like to run a study looking at cells treated with LEP and the 
Akt inhibitor. I showed that the Akt inhibitor only caused even greater increases in p27 
protein with co-treatment with ADIPO. If I find that all of LEP negative effects on the cell 
cycle proteins, specifically on ADIPORl, are abolished I can then say more concretely 
that the effects discovered with LEP are due to increases in Akt. 
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Also in the future I plan on looking at serum samples from both obese and lean 
breast cancer patients in order to determine if the same results discovered with the 
adipocyte conditioned media persist with the in-vivo samples. I will also look to add on 
to my current HFD and CD rat study by adding an exercise group in order to determine if 
I can cause an increase in ADIPORl in non-transfected MCF7 cells. Also interestingly will 
be whether this exercise group can further increase the positive effects ADIPORl 
transfection had on cell cycle proteins and whether it can further overcome the negative 
effects caused by a HFD. 
With all studies there are limitations to my study and it is important to 
understand them in order to make future studies even stronger. Although I utilized an 
adipocyte conditioned media experiment, it doesn't classify as a direct in-vivo 
experiment. Although all the adipokines are present in the adipose tissue are in the 
media, the system itself is not present. I think it would be beneficial to utilize a direct in-
vivo model, by injecting both non-transfected and ADIPORl transfected MCF7 cells 
subcutaneously into immunocompromised rats. We could then determine whether the 
increase in ADIPORl causes the tumor cells to grow slower by utilizing more ADIPO from 
within the circulation in-vivo. 
Another limitation could be the concentrations of ADIPO that were used in the 
study. The concentrations used are considered subphysiological and could be viewed as 
a limitation to the study. The decision to utilize 9 nM (150 ng/ml) and 18 nM (300 
ng/ml) concentrations of globular ADIPO came from the ADIPO optimization 
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experiment done with pAMPK in my thesis as well as previous work done within our lab 
on MCF7 cells 113• The LEP concentrations of 150 nM (2500 ng/ml) and 300 nM (5000 
ng/ml) used was also determined from the LEP optimization experiment as well as 
previous research in our lab that look at LEP effects on pAMPK and p27 protein levels 113• 
Although the levels of ADIPO are below that which is considered physiological, I show 
that the ratio between ADIPO and LEP is of importance and not the absolute 
concentrations and that the same results persist even at physiologically relevant 
conditions in the CM experiments. 
Overall, I believe this thesis gives insight into the mechanisms underlying the 
adipokine status of breast cancer patients. This study further stresses the importance of 
the ratio between ADIPO:LEP and how obesity can play a pivotal role in creating a 
positive growth environment for breast cancer cells. Further investigation, I believe will 
elicit the exact mechanisms by which ADIPO and LEP elicit their response on the cell 
cycle regulatory proteins. 
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